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ABSTRACT
IDENTIFYING THE SIGNALING MECHANISMS
OF EGFR-MEDIATED APOPTOSIS
Nicole Marion Jackson
March 7, 2017
The Epidermal Growth Factor Receptor (EGFR) is a 170-kilodalton
transmembrane protein that belongs to the ErbB family of receptor tyrosine
kinases. Upon ligand-mediated activation, the EGFR is responsible for cell
growth, proliferation, and tissue homeostasis; however, the EGFR is
overexpressed in many human malignancies, including MDA-MB-468 cells, a
metastatic breast epithelial cell line. Studies within this cell line, and other cell
lines characterized with high EGFR levels, have shown that EGF stimulation
results in the induction of apoptosis. However, the mechanisms and signaling
effectors implicated in this process have yet to be elucidated. The overarching
research goal of this dissertation was to better understand the molecular
mechanisms employed by the receptor that result in the induction of apoptosis in
MDA-MB-468 cells. Identifying key regulators/mediators of EGF-induced
apoptosis will help elucidate new pharmacological targets that better attenuate
cell growth in cancers characterized by EGFR hyperexpression.
Through an extensive review of the literature, we have identified Cyclic
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GMP dependent protein kinase (PKG) and Signal Transducer and Activator of
Transcription 3 (STAT3) as potential signaling intermediates of EGF-induced
apoptosis. EGF stimulation resulted in a dose-dependent increase in PKG
activity. Agonists of PKG did not induce EGFR activation, confirming that PKG
activity occurred downstream of receptor activation. RNA Interference (RNAi)
targeting PKG resulted in a significant reduction in EGF-induced cell death, as
well as a reduction in apoptosis. Similarly, we used siRNA to ablate STAT3
activity, which resulted in a significant attenuation of apoptosis, as measured by
PARP cleavage. Additionally, cytokine-mediated (EGFR-independent) activation
of STAT3 induced PKG activation, and resulted in a significant induction of
apoptosis that was sustained over time.
Together, our results indicate that PKG and STAT3 are molecular targets
for cancers with high levels of EGFR, and that activation of proteins that induce
cell death may be more beneficial, therapeutically, than antagonizing proteins
that promote cell growth.
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CHAPTER I
BACKGROUND AND INTRODUCTION

A.

EGFR

The epidermal growth factor receptor (EGFR) is a cell surface receptor
that is expressed ubiquitously throughout the body and plays critical roles in
development and tissue homeostasis. Further, many cancers are characterized
by hyperactivated EGFR signaling, either due to overexpression of the receptor
or somatic activating mutations of the receptor. These perturbations in EGFR
expression and/or activation are associated with poor patient prognosis. Over the
last 15-20 years, there has been a concerted effort to develop cancer
therapeutics that specifically target the aberrant EGFRs, with the goal of
inhibiting the progression of those cancers. Understanding the basic cell biology
of the EGFR helps to understand its implications, and define its typical role in
normal cell biology.
In order to better understand the function of the EGFR, it is best to start
with the discovery of one of the principal ligands that initiates its activity. Dr.
Stanely Cohen isolated and discovered its endogenous ligand, Epidermal Growth
Factor (EGF) from murine submaxillary glands in the early 1960’s. Frozen
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submaxillary glands were obtained from mice and homogenized in acetic acid,
prior to being frozen in a dry ice-alcohol bath. The material was then thawed and
subjected to a series of ultra-centrifugations at 100,000 x g, and acetic acid
washes. The newly formed pellet was then subjected to size exclusion, and ion
exchange chromatography for purification [1]. Amino acid analysis of the purified
product revealed that EGF is a 53 amino acid residue polypeptide, containing
three internal disulfide bonds, as depicted in Figure 1.1.
Dr. Cohen observed that injecting the purified, crude, submaxillary gland
preparations into newborn mice stimulated growth of embryonic neurons and
induced precocious eyelid opening. Having identified a growth factor that was
able to initiate some very specific physiological responses, the next goal was to
identify the receptor. In 1978, he and Dr. Graham Carpenter were able to identify
the presence of the 170-kilodalton EGFR specific for EGF ligand through the use
of radiolabeled (125 I-labeled) EGF ligand in A-431 cells, a human epidermoid
carcinoma cell line. They reported increased 32P incorporation in the A-431 cells
in response to EGF ligand stimulation, suggesting that phosphorylation of EGFR
components might be critical for its function [2]. In 1982, Dr. Cohen proceeded to
then successfully isolate and purify the EGFR from A-431 cells, and from normal
mouse liver cells by means of affinity chromatography. Purification of the
receptor aided in the confirmation that the EGFR was able to bind 125 I-labeled
EGF, and that the receptor possessed ligand stimulated, intrinsic kinase activity,
which was responsible for auto-phosphorylation of tyrosine residues, upon
binding of EGF. This particular study also confirmed that the receptor in normal
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liver cells had biochemical similarities to receptors found in the carcinoma cell
line [3]. The contributions of Dr. Cohen and Dr. Carpenter have allowed for
subsequent studies to unveil further information about the receptor, including its
physiology, function, and regulation.
Another huge leap in our understanding of the molecular mechanism of
EGFR-mediate signaling came in 1984 when Ullrich and colleagues used the
newly identified tools of molecular biology to clone the human EGFR. From this
report, a model (which has been modified numerous times over the years) was
generated that described the functional domains of the EGFR.
The EGFR is comprised of three major domains: 1) an extracellular, ligand
binding domain with cysteine rich regions, 2) a cytosolic, intrinsic kinase domain,
and 3) a cytosolic domain containing tyrosine residues (Fig 1.1) [4]. Studies by
Lax et al. devised a method utilizing 125 I-labeled EGF to label the EGFR for
subsequent isolation, and cleavage through use of Cyanogen Bromide (CNBr).
Site-specific antibodies were then used to identify certain residues (294 and 543)
that are critical for the function of the receptor. On the basis of amino acid
sequence conservation, it was then determined that the extracellular domain is
comprised of 621 amino acid residues, and could be divided into 4 sub-domains
[5]. Domains I and III are ligand binding regions, with 37% homology that
physically bind the ligand. Domains II and IV are rich in cysteine, and have 17%
amino acid homology that interfaces with other receptors for dimerization [6, 7].
The model of how these domains come together is based on
crystallographic analysis that was done by the Lemmon laboratory. In the
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Figure 1.1 EGFR Domains and Activation (Adapated from Brian P. Ceresa).
The EGFR is comprised of a ligand binding domain, and intracellular kinase
domain, and a domain containing tyrosine rich region at the cytosol. Ligand
binding induces a conformational change at the ligand biding domain, which
allows for two receptor monomers to dimerize and form an active receptor:ligand
complex.
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unliganded state, the cysteine-rich domains of a monomeric receptor bind to one
another through an intramolecular interaction. Upon the introduction of ligand,
the receptor undergoes a conformational change such that both ligand binding
domains bind the ligand and disrupt the interaction between the two cysteine rich
domains. The exposure of cysteine rich domain I then can interact with the
corresponding domain with another EGFR to form a dimer. Ligand binding also
brings about a conformational change that activates the intrinsic kinase domain,
which then leads to autotransphosphorylation of the cytosolic tyrosine residues
(Fig. 1.1) [8]. The kinase domain of each receptor moiety will phosphorylate
tyrosine residues on its adjacent dimer partner by a conformational change in the
receptor that places the tyrosine substrate in access to the kinase domain. These
phosphotyrosines then serve as docking sites for various cytoplasmic enzymes,
known as effector molecules. By docking to the phosphotyrosines, these
effectors become activated and modulate various cellular processes that
contribute to the overall cell biology [9]. Activation of alternative downstream
signaling cascades by the EGFR induces known responses for cellular
differentiation, proliferation, migration, and protection from apoptosis [10].
Although the EGFR is expressed at the cell surface of many normal cells
and is critical for animal development and cellular homeostasis, it is often
mutated and/or hyper-expressed in a number of human malignancies [11]. In a
study conducted by Real et al., mouse monoclonal antibodies specific for the
EGFR were used to assess the distribution of the receptor in various human cell
and tissue types. These studies have confirmed EGFR expression in normal

5

stomach, bladder, colon, esophageal, and lung tissue; however, no expression
was determined in normal brain tissue or skeletal muscle [12]. In regard to
malignant cells and tissue, the EGFR has shown to be hyper-expressed in colon,
kidney, lung and sarcoma cancers; however, it is non-prevalent in primary
melanoma [12] and gliosarcoma malignancies [13].
In the analysis of large populations of cancers with EGFR mutations, one
of the most common mutations entails a deletion of exons 2-7 of the EGFR gene
that removes virtually the entire extracellular domain of the receptor. In the
absence of a ligand binding domain or cysteine rich domains that have
intramolecular binding to prevent dimerization, this receptor is free to associate
with other mutant receptor and is constitutively active. This mutant receptor is
referred to as EGFRvIII, and is substantially expressed in patients with
glioblastoma malignancies [14, 15]. Mutated tyrosine residues of the EGFR at the
cytosol have also been shown to induce aberrant signaling as well as drug
resistance in cancers characterized by hyper-expression of the EGFR [16, 17]. In
addition to the EGFR itself, studies have shown that alterations in EGFR ligand
expression can hinder certain tissue physiology. Luetteke et al. bred knockout
mice that lacked endogenous expression of various, endogenous EGFR ligands.
Pups born to these knockout mice were runted, and showed stunted growth and
survival. These data provide confirmation of a requirement for EGFR ligands to
initiate receptor signaling in order for proper development of the mouse
mammary gland [18]. Overall, it can be inferred that regulation of tyrosine
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phosphorylation as well as endogenous EGFR ligands are both critical for proper
signaling and modulation of cellular effects of the activated receptor.
Numerous cellular processes play a role in controlling EGFR activity. Chief
among these is ligand-mediated endocytosis. Co-incident with ligand binding to
the EGFR and activation of the intrinsic kinase domain, the ligand:receptor
complex is internalized into the cell in either a clathrin-mediated, or clathrinindependent manner. Clathrin-coated vesicles were first identified in osteocytes
[19], and then later in neurons [20]. In 1975, Barbara Pearse biochemically
characterized these clathrin-coated vesicles as transport vesicles upon isolating
and purifying them from pig brains prior and analyzing their physical properties
via electron microscopy. She described these vesicles as intracellular vesicles
with unique “coats” on their cytoplasmic surfaces [21]. Her discovery serves as
the foundation of biochemical studies entailing clathrin-mediated endocytosis and
membrane trafficking in general.
Sigusmund et al. stimulated receptor activation with EGF for 2 minutes in
HeLa cells prior to immunostaining and subjecting the fixed cells to
immunoelectron microscopy. Immunoelectron microscopy allowed for viewing
and imaging of the immunostained cells in their various compartments during
EGFR mediated endocytosis [22]. These studies, as well as subsequent studies,
revealed that Clathrin-mediated EGFR endocytosis is observed at all ligand
concentrations, where as with higher concentrations of ligand, (10-100 ng/mL)
the receptor undergoes Clathrin-independent endocytosis via caveole [23, 24].
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Once internalized within the cell, the EGFR is subjected to the endocytic
pathway, a pathway responsible for sorting and determining the ultimate fate of
the internalized ligand:receptor complex. An intermediate vesicle containing the
ligand:receptor complex fuses with an early endosome. The mildly acidic
environment of the early endosome (pH 6) allows certain EGFR ligands (EGF
and transforming growth factor–alpha (TGFA)) to dissociate from the EGFR,
should the ultimate fate of the receptor be recycling back to the plasma
membrane [25]. From here, the unbound-receptor will recycle back to the cell
membrane via recycling endosomes for additional ligand binding and signaling.
These recycling endosomes, slightly acidic at pH 6.4, are centered around the
microtubule-organizing center [26]. These recycling endosomes exhibit tubularvesicular morphology, which suggests dynamic trafficking activity and supports
their involvement with the underlying connection of endocytosis with exocytosis
[27, 28]. Should the ligand:receptor complex remain inside of the early
endosome, however, the early endosome will mature into a late endosome with
the complex intact. The late endosome then fuses with the lysosome just prior to
the ultimate degradation of the ligand:receptor complex [29]. This endocytic
pathway is essential for regulating the activity of the EGFR, both temporally and
spatially. Temporally, meaning that the time it takes the receptor to transverse
the entire endocytic pathway will ultimately dictate the duration of its signaling.
Spatially, in regard to the fact that at different subcellular locations, the receptor
will interact with different effector proteins, activating different signaling cascades
[30].
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Due to hyper-expression of the EGFR in a number of human
malignancies, including kidney, breast, pancreatic, and cervical cancers [31], the
correlation between signaling by the EGFR and the endocytic pathway has
important implications in both receptor tyrosine kinase and cancer biology [30].
One approach utilized to assess this correlation involves studying EGFR
signaling and endocytosis upon activation with different ligands. Currently, there
are seven identified growth factors that are able to bind to and activate the
EGFR: these include EGF, amphiregulin (AREG), betacellulin (BTC), epigen
(EPGN), epiregulin (EREG), heparin-binding EGF-like growth factor (HBEGF),
and transforming growth factor- α (TGFA) [32]. Although each of these ligands
stimulate EGFR activation and internalization, they yield diverse effects on
endocytic sorting [33]. This information can be used advantageously to assess
the differential effects and regulatory mechanisms different ligands have on
EGFR signaling. One of the critical components of this dissertation entails
determining if EGFR ligands have differential effects on EGFR-mediated
apoptosis.
EGF is a 53 amino acid, 6.4 kilodalton (kDa) protein that has been shown
to be involved in regulation of cellular proliferation in mammals [34, 35]. Similarly
to EGF, TGFA ligand contains 50 amino acids and has a molecular weight of
approximately 6 kDa. Both EGF and TGFA bind the EGFR however; however,
TGFA binds with 10-30 fold less affinity to the receptor in rat hepatocytes in
comparison to EGF. Thoresen et al. isolated hepatocytes from Wistar rats prior to
stimulating the cells with increasing concentrations of 125 I-EGF and 125 I-TGFA.
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Surface binding curves after 24-hour ligand exposure exhibit a binding affinity of
11.9 nM for TGFA, and 0.42 nM for EGF. The data within this study suggest that
the two ligands compete for a single population of binding sites in rat
hepatocytes, although EGF has a significantly higher binding affinity for the
EGFR than TGFA [36]. It is important to note that TGFA is synthesized and most
prevalent in cancer cells, and cells transformed by oncogenes and retroviruses
[37]. BTC, a slightly larger ligand (9 kDa) comprised of 80 amino acids, was
originally isolated from mouse insulinoma cells, and is able to activate EGFR and
ErbB4 [38]. Studies utilizing 125 I-BTC in Balb/c 3T3 fibroblasts confirm a binding
affinity of 0.5 nM for the EGFR, and suggest that the preferred receptor for BTC
is the EGFR [39].
All three of these ligands are able to bind to the EGFR, and stimulate
kinase activity; however, they differ in regard to their binding affinities to the
EGFR, and their ultimate fates upon endocytosis and endocytic trafficking (Fig.
1.2). In order to compare ligand internalization upon EGFR stimulation,
Roepstorff et al. used an approach of pre-binding various EGFR ligands on ice to
view the synchronized wave of receptor internalization. After determining optimal
incubation time using 125 I-EGF, HEp2 cells were incubated with increasing ligand
concentrations for 100 minutes. The amount of total cell surface receptors was
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Figure 1.2. Model depicting how differential EGFR endocytic sorting
depends on the ligand to which the receptor is bound (Adapted from
Roepstorff et al., Traffic, 2009). When bound to HBEGF and BTC ligands, the
receptor is preferentially targeted for lysosomal degradation. In contrast, AR, EPI,
and TGFA ligands almost always promote recycling of the EGFR to the plasma
membrane (PM). EGF stimulation leads to receptor degradation for the majority
of EGFRs, but is noted to promote recycling in some instances.
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then determined via FACS analysis. These data report that EGF and BTC
ligands both target the EGFR for lysosomal degradation. In contrast, TGFA
almost always promotes recycling of the EGFR to the cell membrane within 90
minutes of ligand exposure [33]. EGF and BTC can both withstand the acidic
conditions of the endosomes, dissociating at around pH 5. In contrast, TGFA
rapidly dissociates from the receptor at pH 7, and is unable to withstand the
acidic environment of the early endosome. This therefore causes the ligand-free
receptor to recycle back to the cell membrane [33, 40]. The fate of the EGFR,
whether it is for degradation or recycling, is critical for its duration of signaling,
which will can vary based on different ligands bound to the receptor. This has
ultimate implications in the initiation different signaling cascades.
B.

Summary of Ceresa Laboratory Preliminary Findings.
Although the EGFR is typically associated with cell growth and

proliferation, forms of cancer that hyper-express the receptor often undergo
EGFR-mediated apoptosis. MDA-MB-468 cells are a metastatic breast epithelial
cell line, derived from the M.D. Anderson Cancer Center in Houston, Texas [41].
In this cell line, the EGFR is hyper-expressed, with approximately 1.3 X 106
receptors per cell [42]. Additionally, this cell line has been documented to
undergo EGFR-mediated apoptosis [43]. Given these earlier reports of the EGFR
inducing apoptosis in MDA-MB-468 cells, our lab became interested in further
elucidating the mechanisms entailed within receptor-mediated apoptosis.
Because the endocytic pathway is the primary mode of regulating the receptor
and its duration of signaling, this was logically the best place to begin our studies.
12

Identifying where within the endocytic pathway EGF-induced apoptosis initiated
might provide some insight in terms of the effectors that were involved in this
apoptotic mechanism.
To begin assessing this, polystyrene beads of 0.9-micrometer size,
covalently conjugated to EGF ligand, were employed. The polystyrene bead itself
is too large for clathrin-mediated endocytosis; however, the conjugated EGF is
able to activate the receptor while the bead retains the activated receptor at the
cell membrane. Hyatt et al. showed that when activated and retained at the cell
membrane, the EGFR elicits signals for cell growth; however, once internalized
within the endosomes, the receptor elicits signals for apoptosis, as measured by
Caspase activity [44]. Subsequent studies within our lab went on to further
disclose that there is a defect in endocytic trafficking within the MDA-MB-468 cell
line [44]. Through use of Percoll gradient and indirect immunofluorescence
assays, Rush et al. showed that instead of traversing the entire endocytic
pathway to the lysosome for degradation, the EGFR accumulates on the limiting
membrane of the early endosome in this cell line [45]. These preliminary studies
set the premise for the work described within this dissertation, which entailed
furthering our findings by identifying protein effectors with direct implications in
mediating EGF-induced apoptosis.
It has been established that the EGFR is a transmembrane tyrosine
kinase with critical implications in normal cell growth, proliferation, wound
healing, and tissue homeostasis. It is regulated in both a spatial and a temporal
manner. Trafficking of the receptor can vary depending on the ligand it is bound
13

to. The EGFR is however hyperexpressed in mammalian cancer [31]. There is
more known about EGFR cell biology in non-malignant tissue, more than in
cancer cells. Research has shown that pharmaceutically available EGFR
inhibitors provided to cancer patients triggers autophagy, a degradative process
that actually helps cancer cells withstand nutrient-poor conditions [46]. Therefore,
it is of interest to employ other strategies and therapies, to better attenuate
malignant cell growth and induce cell death and/or apoptosis.

C.

Cell Death and Apoptosis

The EGFR is typically associated with cell growth, development and tissue
homeostasis; however, it has been also known to mediate cell death in cancers
that hyperexpress EGFRs [43, 47, 48]. Using a cell line that undergoes EGFRmediated apoptosis uniquely allows for the enlightenment of the biochemical
regulation of signaling by using a sensitive, tractable and irreversible readout.
These findings can be used to better understand other signaling pathways and
biological responses to cell growth, and its counterpart, programmed cell death.
The term apoptosis entails the process of programmed cellular death in
both single-cellular and multicellular organisms. Programmed cell death refers to
the time and position of cell death during development of a given organism. It has
many functions during the development process, including adjusting and deleting
cell numbers [49]. Both apoptosis and programmed cell death are normal
processes in growth, development and aging as a homeostatic mechanism for
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proper maintenance of cell populations in tissues [50]. John Kerr first used the
term apoptosis in 1972, in order to describe a morphologically distinct form of cell
death. Through the use of light and electron microscopy, morphological events
that occur during apoptosis have been identified [51]. The process of apoptosis
entails structural changes that take place in two distinct stages: During stage
one, the cell rounds in shape, shrinks, and breaks into well-preserved fragment.
Its nuclear and cytoplasmic compartments condense, causing the cellular
organelles to become more tightly packed as well as fragmented [50, 52].
Pyknosis, or chromatin condensation, is a key characteristic component of
apoptosis [50]. During the second stage, the apoptotic body, a small sealed
membrane that is released by cells undergoing programmed cell death [53], is
taken up by other cells just prior to being degraded and broken down within the
lysosome [52]. This helps to remove any superfluous material, and provide
nutrients that were once in the apoptotic cell to the cell that is viable [54]. The
apoptotic process is a critical component in normal human embryonic
development, and tissue homeostasis in all living organisms [50, 55]. However,
cancer cells often have the ability to avoid apoptosis, and continue to proliferate
[56]. This dysregulation of apoptosis is associated with many malignancies,
including breast, ovarian and colon cancers [57, 58]. Consequently, this can lead
to cellular accumulation within a given organism, creating a permissive
environment for genetic instability and oncogene activation. These events are
known to disrupt cell turnover and function, as well as damage and kill healthy,
viable cells [59].

15

Alternatively to apoptosis, cell death can also occur in a necrotic manner.
Necrosis is considered to be a degradative, toxic process that consequently
induces cell swelling [60, 61], opposite of apoptosis [60]. Necrosis is an
uncontrolled process and requires no energy input. It typically affects a large
population of cells, and causes inflammation, in vivo. Conversely, apoptosis is a
controlled and energy-dependent process that does not induce inflammation, and
can occur in individual cells as well as large clusters of cells [50]. The manner of
cell death by either necrosis or apoptosis depends on the nature of the tissue
type, its developmental stage, and the cell death signal itself [62].
There are several biochemical modifications of apoptotic cells, which can
be used to help differentiate and identify them. Such modifications include DNA
breakdown, phagocytic recognition, and protein cleavage and cross-linking [63].
The caspase proteins are a family of aspartic acid-specific proteases that have
proteolytic activity and are major effectors of apoptosis [50, 64]. They are
normally synthesized as inactive precursors, or pro-enzymes, and only become
activated upon the induction of apoptosis. The pro-enzymatic form gets cleaved
and activated by other caspases, initiating a signaling cascade as well as
apoptosis induction [64]. Currently, there are 14 caspases that have been
identified [65]. These are categorized into three subgroups based on their
function within the signaling cascade. Initiator capsases (caspases 2, 8, 9, and
10) begin the cascade by activating and cleaving the executioner caspases
(caspases 3, 6, and 7) at aspartic acid residues. Once executioner caspases are
activated, they cleave and activate other cellular substrates, such as poly (ADP-
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ribose) polymerase (PARP), which begin the apoptotic process [50, 66]. The third
subgroup of caspase proteins includes caspases 1, 4 and 5, which have more
active roles in inflammation [67]. It should be noted however that Caspase-1 has
been documented to induce PARP cleavage [68], suggesting that PARP
activation can occur in manners mediated by intrinsic and extrinsic pathways of
apoptosis.
Mechanistically, apoptosis is quite complex, involving two main pathways:
the extrinsic and intrinsic pathways (Fig. 1.3). The extrinsic signaling pathway
entails initiating apoptosis via transmembrane receptor-mediated interactions.
These receptors are known as “death receptors”, and are members of the tumor
necrosis factor (TNF) receptor family [69]. Members of this family have a “death
domain”, which is a cytoplasmic domain comprised of 80 amino acids.
The death domain of TNF receptors is primarily responsible for relaying
signals for cell death from the cell membrane to the intracellular signaling
pathways [50, 70]. Upon ligand binding, adapter proteins are recruited to the
death receptors at corresponding death domains. For instance, Fas ligand, a
ligand with a known biological function of inducing apoptosis [71], binds to the
Fas receptor, a member of the TNF receptor family. This ligand-receptor
interaction promotes the intracellular recruitment of the FADD adapter protein
[72]. FADD then associates with procaspase-8, forming a death-inducing
signaling complex (DISC). This then results in the auto-catalytic activation of
caspase-8 from procaspase-8 [73]. The activated caspase-8 then activates
executioner caspases, which leads to the induction of apoptosis. Defects in Fas
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Figure 1.3. Schematic representation of the intrinsic and extrinsic
signaling pathways resulting in the induction of apoptosis (Adapted from
Elmore et al., Toxicol Pathol., 2007). The intrinsic signaling pathway of apoptosis
initiates apoptosis in a non-receptor mediated manner, via mitochondrial-initiated
signaling events. The extrinsic signaling pathway entails initiating apoptosis via
transmembrane receptor-mediated interactions. Both pathways mediate
apoptosis via Caspase cleavage and subsequent activation.
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ligand and Fas receptor are causes of various autoimmune diseases. It has been
shown that upon knocking out the fas gene by homologous recombination,
generalized lymphoproliferative disease (gld) can be completely recapitulated in
mouse models [74]. Similarly, gld can be completely cured by simply expressing
the normal fas gene in the same knockout mice [75]. These studies exhibit how
critical Fas-induced apoptosis is to the regulation and cellular homeostasis of
immunocompromised organisms.
The intrinsic signaling pathway of apoptosis initiates apoptosis in a nonreceptor mediated manner. This pathway entails mitochondrial- initiated events,
involving certain stimuli that send intracellular signals to act on specific targets
within the cell. These intercellular signals can be positive or negative signals.
Negative signals often lead to withdrawal of certain growth factors, which fails to
suppress death processes and essentially triggers apoptosis. On the other hand,
positive signals include those for free radicals, toxins, and viral infections [50].
Apoptotic signals originating from the cell surface lead to the release of
cytochrome c from the mitochondria into the cytosol, where it ultimately binds to
the Apoptotic Protease Activation Factor-1 (Apaf-1). The binding of cytochrome c
to Apaf-1 initiates apoptosome formation, which catalyzes the activation of
caspase 9 [50, 76]. Identical to the extrinsic pathway of apoptosis, activation of
caspase 3 then leads to the downstream induction of apoptosis.
Apoptosis and programmed cellular death are normal processes within the
lifespan of the cell. There are key physiological and morphological features that
distinguish apoptotic cells from necrotic and viable cells. The EGFR is implicated
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in apoptosis in cell lines that hyperexpress it. Data from the Ceresa laboratory
indicate that in addition to undergoing EGFR-mediated apoptosis, this apoptotic
process is spatially regulated within MDA-MB-468 cells. Progression within this
project involves determining necessary protein components implicated in EGFRmediated apoptosis. Through an extensive review of the literature, two candidate
proteins have emerged as potential signaling intermediates in EGFR-mediated
apoptosis: Cyclic GMP Dependent Protein Kinase (PKG) and Signal Transducer
and Activator of Transcription 3 (STAT3). This dissertation describes our findings
in terms of defining each of their individual roles in EGF-induced apoptosis.

D.

Protein Kinase G (PKG)

Cyclic guanosine monophosphate (cGMP), a second messenger protein
derived from GTP, elicits downstream signaling events through interactions with
intracellular receptor proteins. It has implications in the regulation of smooth
muscle tone, cardiac protection, bone growth, platelet aggregation, and
regulating apoptosis [77-79] (Fig. 1.4). Nitric Oxide (NO), produced from nitric
oxide synthase, is the first component involved in the activation of cGMP. NO
diffuses through the plasma membrane of the cell to activate NO-soluble
guanylate cyclases, which subsequently increase cGMP levels. Cyclic-GMP then
proceeds to bind to and activate a number of downstream substrates [78]. One of
the more prominent receptor substrates of cGMP is the cGMP-dependent protein
kinase, or Protein Kinase G (PKG). PKG was first discovered in 1970 in the
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muscle of lobster tails [80]. It is a serine/threonine protein kinase whose
substrates include receptors, enzymes and ion channels [81] (Fig. 1.4).
The binding of 2 cGMP molecules is required for the complete activation
of one PKG molecule [81]. (Fig. 1.4). PKG is a homodimer consisting of two of
the same monomers, each of which contains a regulatory domain and a catalytic
domain on one polypeptide chain [77-79, 81]. Dimerization, auto-inhibition, and
autophosphorylation all occur at the regulatory domain [78]. The catalytic domain
contains a conserved threonine residue, whose phosphorylation is critical for
relieving auto-inhibition, and essentially for kinase activity [78, 82]. PKG exists in
two homologous forms: PKG I and PKG II. PKG I is localized within the
cytoplasm whereas PKG II is generally associated with the cell membrane [81].
Additionally, there are two isoforms of the type I PKG homologue: PKGIβ and
PKGIα. These two isoforms are closely related, except in the N-terminal domain
of the PKGIα isoform, which has 16 fewer residues than the PKGIβ isoform [81].
More recently, the NO/cGMP/PKG pathway has been discovered to play
critical roles in cell proliferation and chemoresistance in cancer cells [83, 84].
Studies have shown that cells that express PKGIα and PKGIβ undergo a
biphasic response when exposed to NO. A low level of NO result in the specific
activation of PKGIα, which induces cell proliferation and suppresses the induction
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Figure 1.4. Schematic representation of intracellular signaling events that
result in PKG activation. Two cGMP molecules must bind to the regulatory
domain of PKG in order to promote PKG homodimer formation. PKG has a few
downstream substrates, which include ion channels and pumps, and enzymes
that regulate intracellular calcium ion concentrations (Wall et.al., PNAS, 2003).
Ultimately, PKG has been well documented to promote smooth muscle
relaxation, cardiac protection, platelet disaggregation, as well as regulate
apoptosis.
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of apoptosis. This is because the PKGIα isoform has a higher sensitivity to NO
than the PKGIβ isoform. Conversely, a high level of NO leads to activation of
both PKG isoforms, and tends to promote cell apoptosis and suppress cell
proliferation. It is believed that the activation of PKGIβ by high-level NO
contributes to the induction of apoptosis in cancer cells [85].
There have also been studies correlating EGFR activity and PKG
activation. When OV2008 cells, an ovarian cancer cell line, were treated with
increasing EGF ligand concentrations, immunoblot analyses displayed increased
phosphorylation of serine-239 residue of VASP, a PKG-specific protein substrate.
Western blot data from this study also exhibit increased phosphorylation of Src, a
non-receptor tyrosine kinase protein that encodes for the SRC gene. These data
suggest that activation of the EGFR and subsequent PKG activation occurs in a
Src-dependent manner [84].
Recently, activation of PKG by cGMP has become of significant interest
as a novel molecular tool in the induction of apoptosis in cancer [86]. PKG
activation has been shown to induce dose dependent decreases in cell viability,
as well as time dependent increases in caspases 3 and 9 activity within the MDAMB-468 cell line. The reduction in cell viability due to PKG activation was
remarkably rescued with the addition of a PKG-specific antagonist to the MDAMB-468 cells [86]. Therefore, it is of interest to explore the activation of PKG and
subsequent induction of PKG-mediated apoptosis in regard to EGFR-mediated
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apoptosis. Correlation of these two apoptotic pathways within the MDA-MB-468
cell line shows potential in identifying a novel protein with direct implications in
the spatial regulation of the EGFR.

E.

Signal Transducer and Activator of Transcription 3 (STAT3)

Signal Transducer and Activator of Transcription (STAT) proteins were
initially discovered as a family of cytoplasm-bound transcription factors, which
mediate normal cellular responses to growth factors, cytokines, and ligands [87,
88]. STAT activation is critical for the mediation of certain biological processes,
including cell proliferation, survival, differentiation, development and inflammation
[89] (Fig. 1.5). To date, there are seven known members of the STAT family
expressed in mammalian tissue: STAT1, 2, 3, 4, 5a, 5b, and 6. During activation,
STAT proteins become phosphorylated at their unique critical tyrosine residues
(Tyr705 for STAT3). This phosphorylation/activation process can be mediated
directly by growth factor receptor tyrosine kinases [90], or via cytokine receptors
through Janus Kinase (Jak) mediation [87, 88, 91] (Fig. 1.5). Phosphorylation
occurs at the cytoplasm, which induces STAT: STAT dimer formation between
two monomers via SH2 domain interactions. From the cytoplasm, the activated
STATS accumulate in the nucleus, where they initiate and mediate gene
transcription by binding to DNA response elements [87]. This results in either
upregulation or downregulation of the biological processes discussed previously,
which are critical for cellular homeostasis (Fig. 1.5).
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Similarly to the EGFR, STAT proteins are implicated in cell growth and
proliferation; however, they are upregulated in cancers and have been known to
induce aberrant signaling in cancer cells. STAT3 has been reported to be
constitutively phosphorylated in human cancer, and has been shown to promote
tumor survival and cancer cell progression [89, 92]. Constitutive STAT3 activity
has been reported in 30-60% of primary mammary malignancies [93]. One study
reports that MDA-MB-468 cells exhibit constitutive activation of STAT3, and that
upon inhibition using a pharmacological inhibitor (5,15-DPP), STAT3:DNA
complexes decrease in a dose dependent manner of inhibitor [94]. These finding
were not observed among the data described within this thesis.
Prior to being implicated in cancer, STAT3-programmed cellular death
was found to be associated with and required for IL-6 induced cell death in
myeloid leukemia [95] and mammary grand involution [96, 97]. After a woman is
finished lactating, the involution process must occur in order to return the
mammary gland to normal size of a “pre-pregnancy” state. This process is reliant
on the post-translational upregulation of STAT3. This leads to downregulation of
serine protease inhibitor 2A (Spi2A), and upregulation of cathepsin B. This
upregulation of cathepsin B leads to the ultimate induction of apoptosis from the
lysosome [98].
It appears as though STAT3 has been shown to play opposing roles in
mammary tissue. In one instance, it has been shown to potentiate cell growth
and invasion when constitutively active in cancer cells. Contrastingly, it has been
implicated in cell death, being required for mammary gland involution, and even
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in leukemia. One of the focuses of this dissertation is to define the role of STAT3
activity in MDA-MB-468 cells.
It has been established that cGMP dependent protein kinase (PKG) plays
critical roles in smooth muscle function and regulation. PKG activity has been
implicated in breast and ovarian cancer. More importantly, PKG activity has been
shown to induce apoptosis in a dose dependent manner of a PKG agonist in
MDA-MB-468 cells [99]. Identifying a correlation between PKG-mediated and
EGFR-mediated apoptosis is therefore of interest for the progression of this
research project. Additionally, STAT3 has also been implicated in cancer.
Although this protein is often associated with cell growth and survival, it is
constitutively active in certain breast cancers, and required for cell death in
certain contexts, such as post-lactation mammary gland involution [98]. The
research within the dissertation entails determining if PKG and STAT3 participate
in the mediation of EGF-induced apoptosis in MDA-MB-468 cells. This
determination, as well as the identification of the exact role of each effector in this
biochemical process, has great potential in improving therapeutic treatments that
target cancers characterized by hyperexpression of receptor tyrosine kinases.

F.

Significance and Statement of Specific Aims

It has been well established that receptor tyrosine kinases (RTK) inhibitors
insufficiently attenuate cancer cell growth over prolonged periods of time [100],
which is due to either acquired or intrinsic resistance of the malignant tissue
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[101]. Therefore, targeting the employed molecular pathways that promote or
attenuate EGFR-mediated cell growth may elucidate more efficacious therapeutic
options for EGFR-associated cancers. Given that EGFR-mediated apoptosis
occurs preferentially in cells with high-level receptor expression, we elected to
use this information advantageously by identifying effectors that had direct
implications in receptor-mediated cell death in a cell line with high EGFR
expression (MDA-MB-468 cells). We identified PKG and STAT3 as potential
candidates of EGF-induced mediators of apoptosis in MDA-MB-468 cells. These
were identified through thorough literature searches, and also through
preliminary data that exhibited that PKG and STAT3 were both preferentially
upregulated with high ligand stimulation, stimulation that coincidently induces cell
death. Therefore, we developed and assessed the following specific aims, and
their respective hypotheses:
Specific Aim 1: Establish the temporal relationship between the EGFR and
PKG activity in the induction of apoptosis in MDA-MB-468 cells.

Aim 1A: Determine if PKG-mediated apoptosis is EGFR dependent.
We hypothesized that EGFR activation induced downstream PKG
activation, resulting in the induction of apoptosis. To assess this hypothesis, we
employed RNAi targeting PKG, just prior to activating the EGFR in MDA-MB-468
cells. Observing an increase in cell viability, coincident with a reduction in
apoptosis would further support our hypothesis and define PKG is a required
mediator of EGF-induced apoptosis.
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Aim 1B: Determine if EGFR-mediated apoptosis is PKG dependent.
We could not abnegate the possibility that our current hypothesis may be
incorrect in regard to the sequence of PKG signaling events. In order to address
this possibility, we elected to assess an alterative hypothesis as well, which was
that within the MDA-MB-468 cell line, PKG activation signals to the accumulating
EGFRs at the endosomes, which then results in the induction of apoptosis. To
assess this hypothesis, we assessed PKG activity within MDA-MB-468 cells
upon cell stimulation with increasing concentrations of EGF. Further, we intended
to antagonize EGFR activity via pharmacological inhibition, stimulate of PKG
activity with PKG agonists before ultimately assessing the outcome on cell
viability and apoptosis. Observing an increase in cell viability, coincident with a
reduction in apoptosis would further support our alternative hypothesis and
define PKG as mediator apoptosis in MDA-MB-468 cells, that functioned via
EGFR activation.

Specific Aim 2: Determine the role of STAT3 in EGFR-mediated apoptosis
in MDA-MB-468 cells.
Similar to our studies entailing PKG, we elected to confirm or refute the
role of STAT3 in either EGFR-mediated cell growth or cell death. In doing so, we
antagonized STAT3 activity via pharmacological inhibition and RNAi-induced
reduction of STAT3 expression. Upon successful STAT3 inhibition and EGFR
activation, observing a reduction in apoptosis would be indicative of a proapoptotic role of STAT3. On the contrary, enhanced apoptosis accompanied with
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an enhanced reduced viability would be indicative of a pro-proliferative,
compensatory EGF-induced cell growth mechanism.
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CHAPTER II
MATERIALS AND METHODS

Cell Lines

MDA-MB-468, A431, and HeLa cell lines were acquired from the American
Type Culture Collection (ATCC). PC3 cells were generously gifted from Dr.
Geoffrey Clark (University of Louisville, Louisville, KY). MDA-MB-468, A431, and
PC3 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% Fetal Bovine Serum (FBS), 1% penicillin, 1%
streptomycin, and 2 mM glutamine. HeLa cells were propagated in similar
conditions, except with less FBS (5%). The cells were maintained at incubation
conditions of 37 ºC in 5% CO2.
All cell lines were serum starved prior to any experimental procedure.
Serum deprivation removes proteins and ligands from serum that could introduce
analytical interference, providing experimental conditions that yield higher
reproducibility [102, 103]. MDA-MB-468 cells were serum starved overnight in
serum free (SF) DMEM (unless otherwise specified in figure legends). PC3 and
HeLa cells were serum starved in SF DMEM for 2 hours prior to beginning of all
experiments. All reagent treatments for MDA-MB-468, HeLa and PC3 cell lines
were prepared in SF DMEM. Preliminary data in the A431 cell line exhibited that
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A431 cells do not retain viability in SF DMEM over prolonged periods of time.
Therefore, A431 cells were always serum “starved” in reduced serum, DMEM
supplemented with 1.25% FBS. A431 cells were subjected to reduced serum for
2 hours prior to beginning all experimental procedures. All reagent treatments for
A431 cell lines were prepared in DMEM supplemented with 1.25% FBS.

Cell Viability Analyses
1. MTT assay
MTT assays were conducted in order to assess cell viability of MDA-MB468-cells upon exposure to agonists of PKG. The MTT assay assesses
mitochondrial dehydrogenase activity based on its ability to cleave the
tetrazolium ring of the MTT reagent (Sigma Aldrich), and subsequently produce
formazan. Only mitochondria of viable cells are capable of such cleavage. Cells
were plated at a density of 5,000-10,000 cells with DMEM supplemented with
10% FBS in a 96 well plate. After a 24-hour incubation period, the cells were
washed with PBS and serum starved for 3 hours in DMEM supplemented with
0.2% BSA. The cells were then treated with various ligands and reagents in order
to induce cell death. After appropriate incubation periods, the MTT reagent (5
mg/mL in PBS) was added to each sample within the 96-well plate. The cells
were then incubated for 2 hours at 37ºC in the absence of CO2. An extraction
buffer (20% sodium dodecyl sulfate, 50% N-dimethylformamide, 50% ddH2O,
80% Acetic Acid, 1M HCl) was then added to all samples of the 96-well plate in
order to extract and solubilize the formazan crystals. After an additional 30-
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minute incubation with extraction buffer at 37ºC in the absence of CO2, the 96well plate was then analyzed on a BioTek Synergy HT plate reader and Gen5
BioTek software, at a wavelength of 570 nm.
2. Alamar Blue Assay
Alamar Blue assays were also conducted in order to assess cell viability
within the MDA-MB-468 cells. Resazurin, the active ingredient in the alamarblue
reagent, is reduced to Resorufin in viable cells. Resorufin is highly fluorescent
and viable cells enhance this fluorescence, which can be analyzed and quantified
on a plate reader. Cells were plated at a density of 10,000 cells in DMEM
supplemented with 10% FBS in a 96-well plate. After a 24-hour incubation
period, the cells were washed with PBS and subjected to serum starvation
conditions described in the previous section. The cells were then treated with
reagents in order to induce either cell growth or death. The cells were then
incubated in the presence of the various reagents for 24-48 hours. The Alamar
Blue reagent was then added as 10% of the sample volume prior to a 2-hour
incubation period. The 96-well plate was then analyzed for fluorescence on a
BioTek Synergy HT plate reader and Gen5 BioTek software, at wavelengths of
530 nm (excitation) and 590 nm (emission).

Agonists and Antagonists

The following agonists of PKG were employed in the research
summarized in Chapter III: 8-Bromoguanosine 3',5'-cyclic monophosphate (8-Br-
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cGMP; Sigma-Aldrich, St. Louis, MO), 8-(4-Chlorophenylthio)-guanosine 3′,5′cyclic monophosphate (8-pCPT-cGMP; Biolog Life Science Institute, Bremen,
Germany), and 8- (4- Chlorophenylthio)guanosine- 3', 5'- cyclic monophosphate,
acetoxymethyl ester (8-pCPT-cGMP-AM; Biolog Life Science Institute, Bremen,
Germany).
STAT3 antagonists, Stattic and S3I-201, were both acquired from SigmaAldrich, and were employed at concentrations specified in the figure legends.
The Oncostatin M (OSM) cytokine was employed as a STAT3 agonist, and was
acquired from PeproTech (Rocky Hill, NJ). EGF ligand was acquired from
ProSpec Protein Specialist (East Brunswick, NJ). Staurosporine (STS) was used
as a positive control for apoptosis, and was acquired from Sigma-Aldrich.

Cell Lysate Preparation and Immunoblot Analyses.

Cell lysates were acquired by washing the cells twice in PBS prior to the
equilibration to 4 ºC and addition of RIPA lysis buffer for cell solubilization (150
mm NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 mm Tris (pH
8.0), 10 mm sodium pyrophosphate, 100 mm sodium fluoride, 2 mm
phenylmethyl sulfonyl fluoride). The lysis buffer/cell mixture was then rotated
end-over-end for 10 min at 4 °C, followed by a 10 minute centrifugation period at
15,000 x g, at 4 °C. The protein concentration of the supernatant from each
sample was then assessed by a BCA assay (Pierce), and samples were
subjected to a 1:3 dilution in SDS sample buffer. Equivalent amounts of protein
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(20-60 µg) were separated by a 10%, 12%, or 15% SDS-PAGE, prior to be being
transferred to nitrocellulose membranes. After being washed in a blocking
reagent to prevent non-specific antibody binding, the membranes were exposed
to various primary antibodies overnight at 4 ºC (All antibodies used are listed in
Table 2.1). After a 1-hour incubation period with HRP-conjugated secondary
antibodies, the membranes were washed in TBS-Tween and visualized by ECL
reagent using a Fotodyne imaging system. All western blot data were analyzed
and quantified using ImageJ software.

siRNA knockdown in MDA-MB-468 cells

Small Interfering RNA (siRNA) targeting PKG-I was acquired from
Dharmacon (Lafayette, CO). Two siRNA oligonucleotides targeting STAT3 (5’GGAGAAGCAUCGUGAGUGA-3’) (5’- CCAUUUGGUGUUUCAUAA-3’) were
also acquired from Dharmacon. Scramble control siRNA (siCON) was acquired
from IDITDNA (Coralville, IA). MDA-MB-468 cells were treated with final
concentrations of 200 nM PKG siRNA, 200 nM STAT3 siRNA or 200 nM siCON
along with INTERFERin (Polyplus Transfection, Strasbourg, France). Cells were
exposed to PKG siRNA for 96 hours and STAT3 siRNA for 72 hours. Cells were
then treated with EGF or STS for maximal time points of 24 or 48 hours,
coincident with maximal siRNA exposure of either 96 hours (for PKGI siRNA) or
72 hours (for STAT3 siRNA). Details of each experiment and subsequent
knockdown verification can be found within the figure legends of the figure
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Figure 2.1 Compilation of all western blot antibodies employed.
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Figure 2.1 Compilation of all western blot antibodies employed (continued)
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containing the respective experiment. Knockdown efficiencies were calculated to
be 55% for PKG siRNA, and 78% for STAT3 siRNA.

EGF-Bead Synthesis
Polystyrene beads of 0.9 µM size (Sigma) were covalently conjugated to
recombinant human EGF (Invitorgen) as previously described [104]. In short,
EGF molecules are conjugated to carboxylate modified, polystyrene beads via
zero length crosslinker, N-(3-Dimethylaminopropyl)-N’-ethylcarbodimide
hydrochlorine (EDAC; Sigma). After rigorous washing, the EGF-beads were
reconstituted and stored in PBS and glycerol. The beads were stored at -20ºC
and were stable for up to 3 weeks.

Statistical Analyses

Treatment groups within each Alamarblue experiment were quantified to
either untreated or vehicle controls in order to generate percent viabilities for
each experimental condition. These percentages for 3 to 4 individual experiments
were then averaged together. Data acquired from both assays are reported as
the means of the percent viabilities ± standard error mean (SEM; n=3). An
unpaired student t-test was then performed for the determination of significance.
Each treatment group was compared to the untreated, serum free (SF), DMEM
control. For the data within Chapter III, Protein Kinase G facilitates EGFRMediated Cell Death in MDA-MB-468 Cells, a p value of less than 0.1 is
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designated significant, and is indicated by a single asterisk (*). A p value of less
than 0.05 is designated significant, and is indicated by two asterisks (**). A p
value of less than 0.001 is designated very significant, and is indicated by three
asterisks (***). A p value of less than 0.001 is designated extremely significant,
and is indicated by four asterisks (****). Within Chapter IV, A p value of less than
0.05 is designated significant, and is indicated by a single asterisk (*). A p value
of less than 0.01 is designated significant, and is indicated by two asterisks (**).
A p value of less than 0.001 is designated very significant, and is indicated by
three asterisks (***). A p value of less than 0.0001 is designated extremely
significant, and is indicated by four asterisks (****)
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CHAPTER III
PROTEIN KINASE G FACILITATES EGFR-MEDIATED
CELL DEATH IN MDA-MB-468 CELLS

Introduction

The Epidermal Growth Factor Receptor (EGFR) is a cell surface receptor
that is expressed in almost every tissue of the body, and plays critical roles in
development and tissue homeostasis [8, 105]. In addition to these physiological
roles, many cancers, such as lung [106], breast [43], and colon [107]
malignancies, are characterized by hyper-activated EGFR signaling, either due
to overexpression of the receptor or somatic activating mutations of the receptor
[43, 47]. Perturbations in EGFR expression and/or activation are associated with
poor patient prognosis. There are a number of FDA-approved therapies that
target the EGFR and attenuate cancer growth. These include small molecular
inhibitors such as Erlotinib and Gefitinib, which has been approved for treatment
of lung [17] and colon [108] cancers, and humanized monoclonal antibodies
such as Cetuximab, which has been approved for treating colorectal cancers
[109].
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Despite the progress in using EGFR inhibitors as a mode of cancer
treatment, these therapies are not failsafe. These drugs can have off-target
effects (i.e. dermatitis, colitis, and corneal erosions) and some cancers become
refractory to the drugs over time [110-112]. EGFR inhibition can also trigger
autophagy in cancer cells, a degradative process that actually helps cancer cells
withstand nutrient-poor conditions [46]. Thus, despite the therapeutic benefits of
EGFR-inhibition, there remains a need for more aggressive and/or targeted
treatments that will arrest cancer growth and progression.
A more comprehensive understanding of how EGFR signaling is regulated
will facilitate the design of new agents. We hypothesize that one key to new
therapies might lie within the cell itself. Paradoxically, cells that overexpress the
EGFR naturally (i.e. A431 and MDA-MB-468 cells [113, 114]) or through
bioengineering [115], undergo apoptosis in response to EGF treatment. By
utilizing this endogenous signaling mechanism we predict that this will specifically
target EGFR-overexpressing cells with minimal side effects to healthy cells.
However, to most effectively utilize these pathways, we need to fully understand
the mechanisms that regulate their signaling.
The goal of this study was to determine the signaling events that occur
downstream of EGFR activation that lead to apoptosis. By determining how
EGFR-mediated apoptosis occurs in cell lines that overexpress the EGFR, we
predict this pathway can be used to halt cancers that express high levels of
EGFR. These studies were conducted primarily in MDA-MB-468 cell line, a
metastatic, breast, epithelial cell line [41]. These cells express approximately 1.3
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X 106 EGFR per cell [42], and have a well documented induction of apoptosis in
response to EGF ligand (≥ 10 ng/mL) [43]
One candidate regulator of EGFR-mediated apoptosis is Cyclic guanosine
monophosphate (cGMP)-dependent protein kinase (PKG). PKG exists in two
functionally indistinguishable forms: PKG I and PKG II. PKG I is localized within
the cytoplasm whereas PKG II is generally associated with the cell membrane
[81]. Additionally, there are two isoforms of the type I PKG homologue: PKGIβ
and PKGIα. These two isoforms are closely related, except in the N-terminal
domain of the PKGIα isoform, which has 16 fewer residues than the PKGIβ
isoform [81]. PKG1 has been demonstrated to be sufficient to induce apoptosis in
MDA-MB-468 cells [99]. PKG is activated by cGMP, a second messenger
produced by the conversion of GTP by guanylyl cyclase (Fig. 1.4). PKG mediates
downstream signaling through interactions with intracellular phosphoproteins
[116], including VASP [117] and Phosphodiesterase type 5 (PDE5) [118]. The
activity of these proteins includes regulating smooth muscle tone, bone growth,
platelet aggregation, and electrolyte and fluid homeostasis. [77-79].
Given that stimulation of PKGI but not PKGII was sufficient to induce
apoptosis [86], we developed the hypothesis that the EGFR mediates apoptosis
though PKGI activity. We find that MDA-MB-468 cells have a reduction in cell
viability and an increase in apoptosis in response to both EGF and PKG
agonists. Further, stimulation of the EGFR leads to enhanced PKG activity in
MDA-MB-468, A431, and HeLa cell lines, as measured by Vasodilator Stimulated
Phosphoprotein (VASP) phosphorylation. PKG stimulation does not enhance
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EGFR phosphorylation in MDA-MB-468 cells, indicative that PKG is downstream
of the EGFR. Further, knock down of PKG decreases the dose dependent
EGFR-mediated cell viability and reduces apoptotic pathways. From these data,
we conclude that in MDA-MB-468 cells, the EGFR utilizes PKG to promote cell
death via apoptotic pathways.
Results
It is well documented that cell lines that hyperexpress the EGFR, such as
MDA-MB-468 cells [43, 119, 120], undergo EGFR-mediated apoptosis. This is
demonstrated with the dose-dependent decrease in MDA-MB-468 cell viability
(Fig 3.1A). How a mitogenic growth factor receptor mediates cell death has
studied for a number of years, with no clear resolution of the molecular
mechanism. Determining the effectors that are necessary for EGFR-mediated
apoptosis is a critical first step understanding the underlying molecular
mechanism.
Based on previous studies linking Protein kinase G (PKG) activity to
apoptosis in MDA-MB-468 cells, we tested whether PKG was downstream of
EGFR activity (Fig 3.1B). Following treatment with EGF, there was a dosedependent increase in EGFR phosphorylation [measured as a function of
phosphorylation of tyrosine 1045 (pY1045)] (Fig. 3.1C). Active PKG
phosphorylates VASP specifically at Serine239 [121]; serine phosphorylation of
VASP is accompanied by a slowed electrophoretic mobility of the protein on
SDS-PAGE resulting in two bands on both phosphorylated VASP (pVASP) and
total VASP immunoblots [122-124].
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Figure 3.1. Increases in EGF ligand concentration elicit a dose dependent
increase in pVASPSer239 phosphorylation in MDA-MB-468 cells. A. MDAMB-468 cells were seeded into 96-well dishes prior to being serum starved
overnight. The cells were treated for 48 hours prior to AlamarBlue, cell viability
analyses. Data are reported as the mean ± SEM (n=3). B. Serum-starved MDAMB-468 cells were treated with varying concentrations of EGF (0, 0.16, 0.5, 1.6,
5 and 16 nM) for 30 minutes. Cell lysates were prepared, and equivalent
amounts of protein (20 µg) were resolved by 12% SDS-PAGE and transferred to
nitrocellulose. Membranes were probed for EGFR phosphorylated at tyrosine
1045 (pY1045), total EGFR (EGFR), VASP phosphorylated at serine 239
(pVASP), total VASP (VASP), and GAPDH as a loading control. Quantification of
EGFR phosphorylation (pY1045) (C.) and VASP phosphorylation (pVASP) (D.)
immunoblots using ImageJ software. Data are plotted as the mean ± Standard
Error of the Mean (SEM) (n=3).
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Using a phosphoVASP immunoblot to monitor activation of PKG, we found
that, co-incident with receptor phosphorylation, there was a dose-dependent
increase in PKG activity (Fig 3.1B). Comparison of the EC50 of EGF-mediated
EGFR and VASP phosphorylation (4.7 nM and 0.49 nM, respectively) indicates
that the processes are tightly coupled; only low levels of EGFR activity are
needed to stimulate PKG.
EGFR:PKG communication is not unique to MDA-MB-468 cells [84]. A431
cells are a metastatic epidermoid cell line that also undergoes EGF-dependent
apoptosis [120], and hyperexpresses EGFRs at levels (1.5 x 106 EGFR/cell
[125]) comparable to MDA-MB-468 [42]. When treated with EGF, A431 cells had
a similar dose-dependent induction of EGFR and VASP activity (Fig. 3.2A). EGF
induced EGFR phosphorylation in A431 cells with a similar efficacy and potency
as seen in MDA-MB-468 cells (Fig. 3.2B). A431 and MDA-MB-468 cells had
comparable levels of pVASP activity (~2-3-fold over basal), and comparable
EC50’s to stimulate pVASP (0.56 nM and 0.66 nM, respectively). Further, in HeLa
cells that expresses much lower levels of EGFR (~50,000 EGFRs/cells [126],
despite a smaller dynamic range of EGFR phosphorylation (Fig. 3.2D), the EC50
was comparable (0.66 nM). Thus, in multiple EGFR-expressing cell lines, there
was an EGF-dependent PKG activation.
Having established that EGFR could activate PKG, we wanted to
determine if direct activation of PKG was sufficient to induce cell death. MDAMB-468 cells were treated with three commercially available agonists of PKG –
8-Bromoguanosine 3',5'-cyclic monophosphate (8-Br-cGMP),
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Figure 3.2. Increases in EGF ligand concentration elicit a dose dependent
increase in pVASPSer239 phosphorylation in A431 and HeLa cell lines.
A. A dose response was conducted in A431 cells using 0, 0.16, 0.5, 1.6, 5 and
16 nM concentrations of EGF ligand. Cells were serum starved for 2 hours, and
then exposed to the various ligand concentrations for 60 minutes. Forty µg of
protein per sample were then resolved on a 10% SDS-PAGE. Western blot data
of pY1045 (B.) and pVASPSer239 (C.) from three independent dose response
experiments in A431 cells were quantified to blots of total protein (EGFR and
VASP, respectively) using ImageJ software. Error bars are expressed as ± SEM.
D. A dose response was conducted in HeLa cells using 0, 0.16, 1.6 and 16 nM
concentrations of EGF ligand. Cells were serum starved for 2 hours, and then
exposed to the various ligand concentrations for 60 minutes. HeLa cell lysates
(60 µg) were then resolved on a 10% SDS-PAGE. Western blot data of pY1045
(E.) and pVASPSer239 (F.) from three independent dose response experiments
in HeLa cells were quantified to blots of total protein (EGFR and VASP,
respectively) using ImageJ software. Error bars are expressed as ± SEM (n=3).
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8-(4-Chlorophenylthio)-guanosine 3′,5′-cyclic monophosphate (8-pCPT-cGMP),
and 8- (4- Chlorophenylthio) guanosine- 3',5'- cyclic monophosphate,
acetoxymethyl ester (8-pCPT-cGMP-AM). 8-Br-cGMP is a brominated derivative
cGMP analog and is cell permeant [127]. 8-pCPT-cGMP and 8-pCPT-cGMP-AM
are both PKG agonists that only differ by the presence of an acetoxymethyl ester;
the addition of the acetoxymethyl ester makes 8-pCPT-cGMP-AM more cell
permeant, and resistant to metabolic turnover [128]. MDA-MB-468 cells were
treated with varying concentrations of these compounds and found to activate
PKG (measured by VASP phosphorylation) (Figs. 3.3A and 3.3B), treatment with
8-pCPT-cGMP did not produce detectable levels of pVASP, likely due to limited
cell permeability, and was not used in cell viability experiments. Importantly, none
of the PKG activators were able to induce detectable levels of EGFR
phosphorylation (Figs. 3.3A and 3.3B). Next, the effect of the PKG agonists on
cell viability was examined. Both 8-Br-cGMP and 8-pCPT-cGMP-AM caused a
modest, dose-dependent decrease in cell viability (Figs. 3.3C and 3.3D).
To determine if the observed decreases in cell viability were a
consequence of apoptosis, we examined caspase-3 and poly ADP-ribose
polymerase (PARP) cleavage via immunoblot analysis. Caspase-3 is a critical
executioner of apoptosis [129]; when active, executioner caspases cleave and
activate various substrates, such as poly ADP-ribose polymerase (PARP), which
ultimately cause the morphological changes associated with apoptotic cells [50,
71]. MDA-MB-468 cells were treated with 8-Br-cGMP, 8-pCPT-cGMP-AM
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Figure 3.3. PKG agonists do not elicit EGFR phosphorylation, but do
induce dose dependent decreases in MDA-MB-468 cell viability. A. The PKG
agonist, 8-Br- cGMP, was used at 0.1, 0.3, 1, 1.3, 2 and 3 mM concentrations.
This treatment was accompanied with a positive control for EGFR
phosphorylation, 16 nM EGF. The cells were exposed to the various conditions
for 1 hour prior to the harvesting of each cell lysate. Forty µg of protein per
sample were then resolved on a 12% SDS-PAGE. B. The PKG agonist, 8-pCPTcGMP-AM (8-p-AM), was employed at 1, 10, and 100 µM concentrations. The
other PKG agonist in use, 8-pCPT-cGMP, was employed at 100, 250, and 500
µM concentrations. Cells treated with serum free DMEM (SF) served as a
negative control for both pVASP and EGFR phosphorylation. Cells treated with
16 nM EGF served as a positive control for EGFR and pVASP-SER239
phosphorylation. C. Results from an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) cell viability assay. Cells were serum starved
overnight, and then subjected to each experimental condition for 48 hours total
prior to MTT analyses. A vehicle control of 6.7% deionized water in DMEM was
used to accompany the 3 mM 8-Br-cGMP treatment. Data are expressed as
means of percent viability ± SEM (n=3). D. Results from an AlamarBlue cell
viability assay. Cells were serum starved overnight, and then subjected to each
experimental condition for 48 hours total prior to AlamarBlue analyses. Cells
treated with the PKG agonist, 8-p-AM, were quantified to their respective vehicle
control (cells treated with 0.2% DMF). All other data were quantified to the serum
free control. All data are plotted as the average of percent viability ± SEM (n=4).
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(8-p-AM) and 16 nM EGF. Cells were collected and analyzed by immunoblot for
the presence of cleaved PARP and caspase 3 (Fig. 3.4). Cells were incubated in
serum free media (SF) and vehicle alone as a negative control and with
Staurosporine (STS) as a positive control. The PKG activators and EGF induced
PARP and caspase-3 cleavage (Fig. 3.4A). Consistent with the cell viability
assays, EGF treatment was more effective than PKG activation (Figs. 3.4B and
3.4C).
Finally, to determine if PKG is a signaling intermediate in EGFR-mediated
apoptosis, we examined EGFR-mediated signaling with attenuated PKG
expression (Fig. 3.5). Cells were transfected with control (siCON) or PKG specific
siRNA, treated with EGF for 24 or 48 hours, and assayed for cell viability (Figs.
3.5A and 3.5B). PKG knockdown was verified by immunoblot (Fig 3.5C) and was
quantified using Image J software to be 55%, consistent with previous reports
[130]. In the absence of PKG, EGF treatment was not as effective at decreasing
cell viability. This was statistically significant after 48 hours of EGF treatment and
at high EGF doses (i.e. 16 nM), however, this trend is observed at all three EGF
concentrations. When PKG knock down cells were treated with EGF, there was a
trend of reduced activity in apoptotic markers (PARP and Caspase-3 cleavage)
(Figs. 3.6B- D), but this was not statistically significant.
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Figure 3.4
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Figure 3.4. PKG agonists induce apoptosis in the MDA-MB-468 cell line.
A. MDA-MB-468 cells were serum starved overnight. With the exception of
Staurosproine (STS), the cells were then subjected to each experimental
condition for 24 hours. MDA-MB-468 cells were treated with STS for 3 hours prior
to being harvested. This was done in order to induce a robust response without
inducing catastrophic damage to the cell. The induction of apoptosis was
determined by using PARP and Cleaved Caspase-3 antibodies. With the
exception of STS, 40 µg of protein per sample were then resolved on a 15%
SDS-PAGE. Fifteen µg of protein from the STS sample were resolved on the
15% SDS-PAGE. This was done in order to ensure that our positive control was
within the dynamic range. Quantification of western blot data from cleaved PARP
(B.) and Caspase-3 (C.) from three independent experiments. Band intensities
were determined using Image J software and plotted relative to total PARP (%
cleaved PARP) or GAPDH (ratio of cleaved Caspase-3/GAPDH), respectively.
Data are plotted as the average ± SEM (n=3).
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Figure 3.5. Reduction in PKG activity yields a significant increase in MDAMB-468 cell viability upon exposure to EGF ligand. MDA-MB-468 cells were
subjected to either 200 nM control siRNA (siCON) or 200 nM of siRNA targeting
PKG for a total of 96 hours. The day after initial siRNA transfection, MDA-MB468 cells were seeded into 96-well dishes and were then subjected to various
concentrations of EGF ligand for either 24 hours (A) or 48 hours (B). Data are
plotted as the average of percent viability ± SEM (n=3) C. Representative
western blot image of 200 nM siCON and 200 nM PKG siRNA exposed MDAMB-468 cells at 96 hours. Cell lysates were loaded in volumes of decreasing
protein concentration (20, 10, and 5 µg) and then resolved on a 12% SDS-PAGE.
Blots were then quantified using ImageJ software in order to determine the
percentage of PKG knockdown (55%).
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Figure 3.6. Reduction in PKG activity yields less apoptosis in MDA-MB-468
cells. A. Representative western blot image of 200 nM siCON and 200 nM PKG
siRNA exposed MDA-MB-468 cells at 96 hours. Cell lysates were loaded in
volumes of decreasing protein concentration (20, 10, and 5 µg) and then
resolved on a 12% SDS-PAGE. Blots were then quantified using ImageJ
software in order to determine the percentage of PKG knockdown (55%). B.
Representative western blot image of western blot analyses of PKG knockdown
and siCON MDA-MB-468 cells. Cells were treated with 200 nM siCON or 200 nM
PKG siRNA for 96 hours. The cells were also exposed to either serum free media
(SF), EGF, or Staurosporine (STS) for 48 hours. Cell lysates were then
harvested and resolved on a 15% SDS PAGE. Immunoblot images for PARP and
Cleaved Caspase-3 were used as indicators of apoptosis. Quantification of
western blot data from cleaved PARP (C.) and Caspase-3 (D.) from three
independent experiments. Band intensities were determined using Image J
software and plotted relative to total PARP (% cleaved PARP) or GAPDH (ratio
of cleaved Caspase-3/GAPDH), respectively. Data are plotted as the average ±
SEM (n=3).
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Discussion

The purpose of this study was to identify effectors downstream of EGFR
activation that are actively mediating apoptosis in MDA-MB-468 cells. Using a
combination of immunoblot assays, pharmacological activators, and RNAi, we
tested the hypothesis that the EGFR is signaling via PKG to induce apoptosis.
The ligand-dependent activation of the EGFR corresponded with phosphorylation
of the PKG substrate VASP (Fig. 3.1B). The directionality of this signaling was
confirmed by the observation that direct activation of PKG with the agonists 8-BrcGMP and 8-p-AM (Figs. 3.3A and 3.3B) failed to stimulate the EGFR. Finally,
when PKG was knocked down, there was a statistically significant reduction in
EGFR-mediated cell viability and a decrease in caspase-3 cleavage.
PKG is not normally associated with a downstream effector of the EGFR.
However, it is not unprecedented; EGF stimulation in an ovarian cancer cell line,
OV2008, leads to an EGFR-dependent VASP phosphorylation as well [84]. In
addition to MDA-MB-468 cells, EGF treatment of A431 and HeLa cells, leads to a
dose-dependent induction of phosphoVASP (Fig. 3.2). It should be noted that in
cell lines which express physiological levels of EGFR, exposure to higher levels
of ligand often elicit total receptor degradation [44] (Fig. 3.2D). EGFR:PKG
communication can occur independent of receptor expression. However, the
cytotoxicity associated with EGFR-mediated PKG activity may be a function of
the kinase’s subcellular distribution, the duration of receptor:effector
communication, or the presence of downstream substrates.

59

While A431 cells undergo EGFR-mediated apoptosis [120, 131], EGF is
not as potent in its induction of apoptosis as what has been observed in MDAMB-468 cells. For instance, it has been reported that A431 cells are capable of
surviving EGF treatment for several days, and can become resistant to the
induction of apoptosis in the presence of EGF [132]. Further, the initial reports of
PKG-mediated apoptosis were in MDA-MB-468 cells [86, 99]. We therefore
elected to pursue subsequent experiments in a cell line with the greatest dynamic
range.
PKG activity is often associated with cytoprotective biology (i.e. heart cells
[133], neurons, and glia cells [134, 135]) rather than a mediator of apoptosis.
However, there is other evidence linking PKG to other proapoptotic effects in
breast [86], ovarian [84], and colon cancer. Activation of PKGI in colon cancer
cells induces apoptosis in a c-Jun NH2 NH2-terminal kinase 1 (JNK1) pathway
dependent manner [136]. Many of the roles of cGMP and PKG signaling are well
understood; however, a lack of clarity remains in terms of the role of PKG in
cancer. This research aims to provide more information about PKG and it’s
association with EGFR, and other receptor tyrosine kinases with implications in
human malignancies.
By most accounts, apoptosis is an aberrant EGFR-mediated signaling
event for a receptor that typical promotes cell growth. It is a challenge to decipher
the molecular events that specifically promote apoptosis in the context of
receptor- and cell stress-mediated pro-growth signaling. As a result, the
molecular details of EGFR-mediated apoptosis remain controversial. The signal
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transducers and activators of transcription (STAT) pathway is one of the most
intensively studied mechanism entailed in EGFR-mediated apoptosis in cancer
[137]. Studies have shown that in cell lines that hyper-express EGFR, the EGFR
activates STAT1, which recognizes responsive elements of and upregulates p21
[138, 139]. When active, p21 is a cyclin-dependent kinase inhibitor that
suppresses reduces cell proliferation and induces apoptosis [140]. More recent
studies have shown that in cell lines with elevated EGFR expression, EGF
stimulation suppresses activity within the phosphoinositide 3-kinase/protein
kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway,
suggesting that inhibition of the PI3K/AKT/mTOR pathway might be required for
EGFR-mediated apoptosis to occur [141].
This report provides data indicating that in MDA-MB-468 cells, PKG
contributes to EGFR-mediated cell death, likely through apoptotic signaling
pathways. Although the contribution of PKG to EGFR-mediated apoptosis
appears modest, this is likely a consequence of partial PKG knock down (~55%
knock down). It remains unclear how a mitogenic growth factor receptor and a
cytoprotective effector collaborate to induce apoptosis. One possible explanation
is that hyperstimulation of cell viability pathways leads to cell catastrophe over
time. Several pieces of evidence support this model. First, cell lines that have low
levels of EGFR and more rapid receptor turnover do not induce apoptosis [45].
Second, low levels of EGF ligand do not induce MDA-MDA-468 cell apoptosis
[43]. Third, the slowed kinetics of cell death following EGFR or PKG activation
argue that the induction of apoptosis does not occur as a direct activation of an
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enzymatic pathway. Nevertheless, the EGFR:PKG communication shows
promise as a new pathway for selectively mediating cytotoxicity in cells that
overexpress the EGFR.
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CHAPTER IV
EGFR-MEDIATED APOPTOSIS VIA STAT3

Introduction

The Epidermal Growth Factor Receptor (EGFR) is a transmembrane
receptor tyrosine kinase that plays critical roles in cell growth, tissue
development, and overall cellular homeostasis [8, 105]. Despite these critical
physiological roles, there are a myriad of human malignancies [43, 106, 107] that
are characterized by hyper-activated EGFR signaling. This is due to either
receptor overexpression or activating mutations of the receptor [43, 47]. The FDA
has approved pharmacological agents that antagonize ligand binding and inhibit
EGFR kinase activity for the treatment of patients with cancers characterized by
hyper-activated EGFR signaling [17, 108, 109]; however, these drugs have offtarget effects (i.e. colitis, corneal erosions and dermatitis) and cancers often
become desensitized to these agents over time [110-112]. Thus, there remains a
need to develop drugs that more aggressively and specifically target those
cancers with enhanced EGFR signaling, but allow normal, healthy cells to
perform biological roles.
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One potential strategy for doing this is to hijack intrinsic signaling
pathways and exploit them to compromise the cell’s health. Cell lines with EGFR
overexpression either naturally (A431 and MDA-MB-468 cells [113, 114]) or via
bioengineering (Rat-1 fibroblasts) [115], undergo EGF-induced apoptosis [43,
119, 120]. Understanding the molecular mechanism by which this occurs will
identify new potential pharmacological targets that can induce death in cells that
overexpress the EGFR (i.e. cancer cells).
Through an effector screen, STAT3 was identified as a plausible mediator
of EGFR-induced apoptosis. Signal Transducer and Activator of Transcription 3
(STAT3) is one of seven members of the STAT family of transcription factors,
namely, STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT7. STAT
activation is critical for a number of biological processes, including cell
proliferation, survival, differentiation, development and inflammation [89]. STAT3
is a DNA-binding transcription factor that is known to mediate normal cellular
processes upon activation by growth factors, ligands and cytoplasmic cytokines,
such as cytokine receptor-associated Janus kinases (JAKs) [87, 88, 142, 143].
These upstream protein components phosphorylate STAT3 at its unique, critical
tyrosine residues, primarily Tyr705 [87, 88]. The EGFR has also been reported to
directly tyrosine phosphorylate STAT3 [93, 144]. STAT phosphorylation occurs at
the cytoplasm, which induces STAT homo and heterodimer formation between
two monomers via their Src homology 2 (SH2) domain interactions. From the
cytoplasm, activated STAT dimers translocate and accumulate in the nucleus,
where they initiate and mediate gene transcription by binding to DNA response
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elements [87]. This results in either upregulation or downregulation of the
biological effectors and subsequent cellular processes that are critical for cellular
homeostasis.
STAT3 has been implicated in the post-transcriptional modification of
cellular processes, positively and negatively affecting cell growth and
proliferation. Aberrant STAT3 signaling and constitutive activity has been
reported in a number of cancers [89, 92]. Elevated basal STAT3 activity has
been reported in 30-60% of primary mammary malignancies, with reports of it
being required for tumor cell progression and metastasis [93]. However, prior to
being implicated in cancer, STAT3-mediated programmed cellular death was
found to be associated with and required for mammary gland involution [96, 97].
Additionally, STAT3 has been previously implicated as a key mediator of
apoptosis in murine pro-B cells [145], myeloid leukemia [95], and prostate cancer
[146]. These conflicting roles for STAT3 in the context of normal and malignant
cellular biology highlight the need for a better understanding of this protein in
EGFR signaling mechanisms.
The overarching goal of this study was to identify mediators of EGFRmediated apoptosis. STAT3 was identified as being specifically activated under
apoptosis-inducing conditions. Based on this finding, we develop two mutually
exclusive hypotheses. First, STAT3 was acting as an active intermediate and
promoting cell death, or second, STAT3 was upregulated as a compensatory
mechanism in an attempt to promote cell survival during EGFR-induced cell
stress. Utilizing siRNA targeting STAT3 resulted in a significant attenuation of
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EGF-induced apoptosis. Additionally, EGFR-independent activation of STAT3
through cytokine stimulation promoted apoptosis, as measured by PARP and
Caspase-3 cleavage. From these findings, we conclude that STAT3 is required
for EGFR-mediated cell death via PARP cleavage and subsequent activation.

Results
It is known that cell lines that hyperexpress the EGFR, such as MDA-MB468 and A431, undergo EGFR-mediated apoptosis [43, 119, 120]; however, the
molecular mechanism(s) by which this occurs have not yet been fully elucidated.
Previously, it has been documented that in MDA-MB-468 cells, lower
concentrations of EGF (0.16 nM) promote cell growth, whereas higher
concentrations (16 nM) induce apoptosis [43]. With this in mind, we screened
MDA-MB-468 cells for the ability to activate five effector proteins that have been
previously associated with cell growth and or apoptosis in cancer: MAPK [147,
148], SRC [149, 150], AKT [147], BAD [151], and STAT3 [95, 152] (Figs. 4.1 and
4.2). MDA-MB-468 cells were treated with either low (0.16 nM) or high (16 nM)
concentrations of EGF for 0-120 minutes, and assessed the phosphorylation
status (activity) of these effectors by immunoblot (Fig. 4.1A and Fig 4.2A). MAPK,
SRC, AKT, and BAD displayed no significant differences in phosphorylation
patterns with the high and low concentrations of ligand (Figs. 4.1B- E). However,
STAT3 phosphorylation
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Figure 4.1
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Figure 4.1. Phosphorylation of MAPK, SRC, AKT, and BAD in response to
high and low EGF concentrations. A. Serum-starved MDA-MB-468 cells were
stimulated with low (0.16 nM) or high (16 nM) EGF ligand for 0-120 minutes. Cell
lysates (20 µg) were resolved by 12% SDS-PAGE and were assessed for the
indicated proteins via immunoblot analysis. Band intensities from the immunoblot
data of pMAPK (B.), pSRC (C.), pAKT (D.) and pBAD (E.) were quantified,
normalized to GAPDH levels, and plotted as the relative level compared to cells
with no treatment. Data are expressed as the average
Mean (SEM; n=3).
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Standard Error of the

(Tyrosine 705), was undetectable at all time points following stimulation with low
concentrations of ligand, but was robustly increased over time following
treatment with high levels of ligand (Figs. 4.2A and 4.2B).
To determine if STAT3 phosphorylation is cell type specific, A431 cells, a
metastatic epidermoid cell line, were employed. MDA-MB-468 and A431 cell
lines both induce apoptosis upon EGF stimulation [120] and express comparable
levels of EGFR [42, 153]. Like MDA-MB-468 cells, A431 cells treated with low
concentrations of EGF did not yield significant increases in pSTAT3, but cells
treated with high concentrations did (Figs. 4.2C and 4.2D).
Next, we monitored STAT3 phosphorylation in MDA-MB-468 and A431
cells following treatment with increasing concentrations of EGF ligand. Data from
the dose-response experiments supported the findings of our time course
experiments, displaying a dose-dependent increase in STAT3 phosphorylation in
both cell lines (Fig. 4.3). These experiments, in two different cell lines, confirmed
that higher concentrations of EGF were required for STAT3 phosphorylation.
Importantly, the concentrations of EGF required for STAT3 phosphorylation were
co-incident with the concentrations required to induce apoptosis. To further
confirm this, EGF-beads were employed in the MDA-MB-468 cell line. Given
previous reports of EGF-beads promoting cell growth within this cell line, we
suspected that if STAT3 were mediating apoptosis in an EGFR dependent
manner, we would observe preferential STAT3 phosphorylation with soluble
EGF, and no phosphorylation with the EGF-beads. Our studies utilizing the
beads resulted in a robust, dose-dependent increase in pSTAT3 with soluble
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Figure 4.2. STAT3 is tyrosine phosphorylated in response to high, but not
low, EGF concentrations. Serum-starved A. MDA-MB-468 and B. A431 cells
were stimulated with 0.16 nM and 16 nM EGF ligand for 0-120 minutes. Cell
lysates (20 µg and 15 µg, respectively) were resolved by 12% SDS-PAGE and
were assessed for phospho-EGFR (pY0145), EGFR, pSTAT3 (Tyr705), STAT3
and GAPDH, via immunoblot analysis. C. MDA-MB-468 and D. A431 immunoblot
data were quantified, and pSTAT3 was normalized to total STAT3. Data are
expressed as the average

SEM (n=3) relative to untreated samples.
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Figure 4.3. EGF phosphorylates STAT3 in a dose-dependent manner in
MDA-MB-468 and A431 cell lines. Serum-starved MDA-MB-468 cells (A.) and
A431 cells (B.) were treated with varying concentrations of EGF (0, 0.16, 0.5,
1.6, 5, 16 nM) for 30 minutes. Cell lysates (40 µg) were resolved by 10% SDS
PAGE and immunobloted for the indicated proteins. C. and D. Immunoblot data
were quantified, and pSTAT3 was normalized to total STAT3. Data are
expressed as the average

SEM (n=3) relative to untreated samples.
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EGF, but no pronounced pSTAT3 in response to increasing volumes of EGFbeads (Fig. 4.4). Our studies with the EGF-beads require us to conduct a doseresponse to determine a range of EGFR phosphorylation with the beads that
induces comparable phosphorylation to that of soluble EGF. The bulky and larger
size of the polystyrene bead inevitably causes steric hindrance, making it
unfeasible to induce phosphorylation of EGFR comparable to 16 nM of soluble
EGF. However, data from Figure 4.4 exhibit that 80 µL of EGF-beads induces
phosphorylation of the EGFR that’s comparably to 1.6 nM of EGF, a
concentration of soluble ligand that is still capable of inducing apoptosis in the
MDA-MB-468 cell line [43]. In comparison to one another, the pSTAT3 bands
that corresponds with 1.6 nM EGF is slightly darker than the corresponding band
generated from 80 µL of EGF-beads (Fig. 4.4). These data further suggest that
STAT3 is preferentially activated with soluble EGF, and might be associated with
EGFR-mediated apoptosis specifically.
Next, to determine if the induction of STAT3 was unique for the EGFR,
we examined another receptor family that stimulates STAT3 to see if it, too,
promoted apoptosis. Oncostatin M (OSM) belongs to the Interleukin-6 (IL-6)
family of cytokines [154]. Like the EGFR, it has established roles in promoting
cancer and tumor formation in malignant prostate [155], lung, head and neck,
and cervical [156] tissue. In addition, OSM has been shown in some cells to
promote apoptosis [157-159]. MDA-MB-468 cells were stimulated with 100 ng/mL
OSM over a course of 96 hours and were assessed for PARP and Caspase-3

72

EGF (nM)

0

0.16 0.5 1.6

EGF-Beads (μL)

5

16

0

20

40

60 80

100 Wash

IB: pY1045
IB: EGFR
IB: pSTAT3
IB: STAT3
IB: GAPDH

Figure 4.4 STAT3 is preferentially upregulated with soluble EGF, and not
with EGF-beads. MDA-MB-468 cells were stimulated with the indicated
concentrations of soluble EGF (nM) and volumes of EGF-beads (µL) for 30
minutes. Cells were then rinsed and lysed as previously describe. Cell lysates
(20 µg) were then resolved on a 12% SDS PAGE and were assessed for pEGFR
and pSTAT3.
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cleavage (Fig. 4.5). In addition to stimulating pSTAT3, OSM activated pVASP, a
substrate of PKG as well as apoptotic pathways (as evident by increases in
cleaved PARP and cleaved Caspase-3)(Fig. 4.5A). Quantification of multiple
assays indicates that OSM-induced PARP cleavage (Fig. 4.5B) and Caspase-3
cleavage (Fig. 4.5C) is comparable to that induced by EGF. Upon exposure to
STS, STAT3 activation was not induced (Fig. 4.5D). Together, these data are
consistent with the hypothesis that multiple cell surface receptors induce STAT3
phosphorylation co-incident with apoptotic pathways.
Having established that STAT3 phosphorylation correlates with high
concentrations of EGF ligand, and preferentially with soluble EGF ligand, we
hypothesized that EGFR-mediated apoptosis occurred in a STAT3-dependent
manner (Fig. 4.6A). On the contrary, STAT3 could have been have been
upregulated with high ligand stimulation as a compensatory mechanism, in a
failed attempt to rescue the cells from an EGFR-mediated apoptotic fate (Fig.
4.6B). To distinguish between these two possibilities, we antagonized STAT3
with pharmacological inhibitors, Stattic and S3I-201, and then stimulated MDAMB-468 and A431 cells with EGF (Figs. 4.7 and 4.8). These cells were assessed
for cell viability and for their ability to induce apoptotic pathways. Caspase-3 is a
well-established executioner of apoptosis [129]. Upon its cleavage and
subsequent activation, it cleaves and activates other downstream effectors that
promote the induction of apoptosis (i.e. poly ADP-ribose polymerase or PARP). If
STAT3 were in fact promoting apoptosis, we anticipated an attenuation of PARP
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Figure 4.5
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Figure 4.5 EGFR-independent activation of STAT3 promotes apoptosis in
MDA-MB-468 cells. A. Serum-starved MDA-MB-468 cells were stimulated with
100 ng/mL of Oncostatin M (OSM) for the indicated times. Control cells were
exposed to serum free DMEM (SF) and or 16 nM EGF for 24 hours. After
harvesting, the cell lysates (40 µg) were resolved by SDS PAGE, and were
immunoblotted for the indicated proteins. Densitometry quantification of western
blot data of cleaved PARP (B.) and cleaved Caspase-3 (C.). The cleaved PARP
band intensities were normalized to and plotted as a percentage of total PARP
bands. Cleaved Caspase-3 bands were quantified to total protein for each
respective sample (GAPDH). Data are expressed as the average

SEM (n=3).

D. Serum-starved MDA-MB-468 cells were stimulated with 3, 10, 30, or 100 nM
Staurosproine (STS) for 4 hours. Control cells were exposed to serum free
DMEM (SF) and or 16 nM EGF for 4 hours. Cell lysates (40 µg) were resolved by
a 10% SDS PAGE, and were immunoblotted for the indicated proteins.
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Figure 4.6. Models of STAT3 Activity and its potential role(s) in EGFRmediated Apoptosis. Model A depicts STAT3 playing a direct role in mediating
EGF-induced apoptosis. Contrastingly, model B depicts STAT3 playing a
compensatory role to promote cellular growth to prevent an EGFR-mediated
apoptotic fate.
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and Caspase-3 cleavage, coincident with enhanced viability in STAT3
antagonized cells. Conversely, if STAT3 were being activated as a compensatory
mechanism, inhibition of STAT3 would not affect induction of the apoptotic
pathways and would likely further decrease cell viability.
Upon exposure to both inhibitors, cell viability analyses revealed a dosedependent decrease in viability in both MDA-MB-468 and A431 cells,
independent of the presence of EGF (Figs. 4.7A, 4.7C, 4.8A, 4.8C). Although
Stattic was more potent than S31-201, and MDA-MB-468 cells were more
sensitive to inhibitor treatments than A431 cells, the trends held in both cell lines.
Complementary with the viability data, we observed a dose-dependent increase
in cleaved PARP and cleaved Capsase-3 phosphorylation. This finding was
observed in both cell lines when cells were treated with 16 nM EGF in
combination with the STAT3 inhibitors. However, coincident with a dosedependent decrease in phosphorylated STAT3, both cell lines displayed a
corresponding decrease in EGFR phosphorylation (Figs. 4.7B, 4.7D, 4.8B, and
4.8D).
We wanted to determine whether these decreases in cell viability were
due to STAT3 inhibition or from a toxicity mediated by the compounds
themselves. To assess whether the compounds were inherently cytotoxic, we
employed the PC3 cell line, a prostatic carcinoma cell line lacking STAT3
expression [146]. Our biochemistry analysis confirmed that PC3 cells do not
express STAT3 and have very low levels of EGFR expression (Fig. 4.9A). PC3
cells exhibited a dose-dependent decrease in

78

Figure 4.7
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Figure 4.7. STAT3 inhibitors attenuate cell viability and EGFR activity in
MDA-MB-468 cells. MDA-MB-468 cells, plated and treated in parallel, were
assessed for cell viability using an Alamar Blue assay. Data from A. Stattic or C.
S31-201 treated cells are expressed as the average

SEM (n=3) relative to

cells treated without serum (SF). Serum-starved cells were pre-treated for 1 hour
with 0 (0.025% DMSO), 0.3, 1, 3, 5, or 10 µM Stattic (IC50 = 5.1 µM; panel B.), or
with 0 (0.5% DMSO), 1, 3, 10, 30, and 100 µM S3I-201(IC50 = 86 µM; panel D.),
followed by the addition of 16 nM EGF (+) for 24 hours. Control cells were
incubated with serum free media alone (SF), media containing 10% fetal bovine
serum (FBS), or 16 nM EGF (EGF) for 24 hours. As a positive control cells were
treated with 1 µM staurosporine (STS) for 4 hours. Cell lysates were prepared
and 40 µg were resolved by SDS-PAGE before being assessed for the indicated
proteins. For STS treated samples, 15 µg of cell lysates were loaded to keep the
signals in the dynamic range. Shown is a representative experimental replicate of
three.
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Figure 4.8
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Figure 4.8. STAT3 inhibitors attenuate EGFR activity in A431 cells. A431
cells, plated and treated in parallel, were assessed for cell viability using an
Alamar Blue assay. Data from A. Stattic or B. S31-201 treated cells are
expressed as the average

SEM (n=3) relative to cells incubated in 1.25% FBS

in DMEM (reduced serum – RS). Serum-starved A431 cells were pre-treated for
1 hour with 0 (0.025% DMSO), 0.3, 1, 3, 5, or 10 µM Stattic (IC50 = 5.1 µM; panel
A.), or with 0 (0.5% DMSO), 1, 3, 10, 30, and 100 µM S3I-201 (IC50 = 86 µM;
panel C.), followed by the addition of 16 nM EGF (+) for 24 hours. Control cells
were incubated with reduced serum media alone (RS), media containing 10%
fetal bovine serum (FBS), or 16 nM EGF (EGF) for 24 hours. As a positive
control cells were treated with 1 µM staurosporine (STS) for 4 hours. Cell lysates
were prepared, 40 µg were resolved by SDS-PAGE, and immunoblotted for the
indicated proteins. Fifteen µg of the STS sample were used to keep the
immunoblot analysis in the dynamic range. Shown is a representative
experimental replicate of three.
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viability upon stimulation with Stattic and S3I-201 (Fig. 4.9B). These data indicate
the STAT3 inhibitors had off-target activity, and an alternative method was
needed to attenuate STAT3 activity and determine its ultimate role in EGFRmediated apoptosis.
Next, we employed STAT3 siRNA as a more selective mode of reducing
STAT3 expression in the MDA-MB-468 cell line (Fig. 4.10). As compared to
control siRNA (siCON), STAT3 reduced STAT3 expression by 78% (Fig. 4.10A).
STAT3 knock down cells were slightly more viable than control cells following
treatment with the high concentrations of EGF required to induce apoptosis (Fig.
4.10B). Biochemically, STAT3 knock down cells had reduced EGF-induced
cleaved PARP and Caspase-3 (Fig 4.10C- E).
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Figure 4.9
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Figure 4.9. STAT3 inhibitors reduce cell viability in STAT3-null, PC3 cells.
A. Serum-starved MDA-MB-468 and PC3 cells were treated with either DMEM
alone (-), or DMEM supplemented with 16 nM EGF (+) for 1 hour. Cell lysates (20
µg) were resolved by 10% SDS PAGE, and immunoblotted for the indicated
proteins. Shown is a representative experiment repeated three times. B. PC3
cells were exposed to treatments of serum free media (SF), DMEM with 0.025%
DMSO (0), 1, 5, 10 µM Stattic; 0.5% DMSO (0), 1, 10, 100 µM S31-201; or 168
nM Staurosporine (STS) for a total of 24 hours. Cell viability was assessed with
an Alamar Blue assay. Data are normalized to cell viability in serum free media
(SF) and expressed as the average

SEM (n=3).
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Figure 4.10
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Figure 4.10. Knockdown of STAT3 attenuates EGFR-mediated apoptosis in
MDA-MB-468 cells. A. MDA-MB-468 cells were transfected with either 200 nM
control siRNA (siCON) or 200 nM STAT3 siRNA for 72 hours. Cell lysates were
prepared, and decreasing protein concentrations (40, 20, and 10 µg) were
resolved by 10% SDS PAGE and immunoblotted for EGFR, STAT3, and
GAPDH. B. Fourty-eight hours post-transfection, siCON and STAT3 siRNAtransfected cells were treated for 24 hours with 0 (SF), 0.16, 1.6, 16 nM EGF or
168 nM Staurosporine (STS) as a positive control. Cell viability was assessed by
an Alamar Blue assay. Data are expressed as the average

SEM (n=3). C.

Cleaved PARP and cleaved Caspase-3 were assessed in siCON and STAT3
siRNA transfected cells. Seventy-two hours post-transfection, cells were
coincidently exposed to SF DMEM and 16 nM EGF for 24 hours or 1 µM STS for
4 hours prior to harvesting. Cell lysates (40 µg) were resolved on either a 10%
SDS PAGE (pY1045, PARP, and GAPDH) or a 15% SDS PAGE (pSTAT3 and
cleaved Caspase-3), and were assessed for the indicated proteins via
immunoblot analysis. Densitometry quantification of western blot data of cleaved
PARP (D.) and cleaved Caspase-3 (E.). The cleaved PARP band intensities
were normalized to and plotted as a percentage of total PARP. The intensity of
cleaved Caspase-3 was normalized to the levels of GAPDH. Data are expressed
as the average

SEM (n=3).
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Discussion

EGFR-mediated apoptosis is a paradox for growth factor receptors.
However, dissecting how a receptor that normally mediates cell growth and
proliferation induces cell death when overexpressed provides an opportunity to
understand receptor signaling and develop strategies for attenuating the growth
of cancer cells with elevated EGFR levels. In this study, we assessed effector
candidates with documented affiliation with EGFR activation [147, 150, 160] and
implication in human malignancies by either promoting proliferation [147, 148,
152, 161] and/or attenuating it [95, 148, 149, 151]. We assessed MAPK, SRC,
AKT, BAD, and STAT3 for phosphorylation following treatment with low (0.16
nM) versus high (16 nM) concentrations of EGF (Figs. 4.1 and 4.2). Among
these, only STAT3 was activated when ligand concentrations were sufficient to
induce the apoptotic pathways. This was not only true for the EGFR, but
cytokine-mediated activation of STAT3 via OSM resulted in the induction of
apoptosis as well (Fig. 4.5).
Pharmacological inhibitors of STAT3 were employed to ascertain the role
of STAT3 on EGFR-mediated apoptosis. As expected, STAT3 inhibitors in MDAMB-468 and A431 cells resulted in a dose-dependent decrease in STAT3
phosphorylation. Unexpectedly, these inhibitors also antagonized EGFR
phosphorylation and decreased cell viability (Figs. 4.7 and 4.8). This cytotoxicity
cannot be attributed only to STAT3 inhibition; STAT3-null, PC3 cells were also
less viable in response to these inhibitors (Fig. 4.9). RNAi proved to be a more
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useful tool for studying the role of STAT3. Knock down of STAT3 with siRNA
significantly attenuated EGF-induced PARP cleavage and also reduced
Caspase-3 cleavage and cell death (Fig. 4.10). These data provide evidence that
support STAT3 as a direct mediator of EGF-induced apoptosis.
Since it was first reported by Armstrong et al in 1994 [162], the molecular
mechanism by which EGFR-mediated apoptosis occurs has remained
controversial. A number of signaling molecules have been reported to be
involved in this process including Etk [163], STAT1 [164], Caspase-1 [48], and
Protein Kinase G [165]. Dissecting the signaling events that emanate from a
hyperexpressed receptor and culminate in cell death are challenging for a
number of reasons. First, high levels of receptors are going to favor the formation
of receptor:effector complexes that may not occur with physiological levels of
receptor expression. Second, cells with elevated receptor expression have
altered kinetics of receptor down regulation through the endocytic pathway [166,
167]. In cells with physiological levels of receptor expression, the EGFR will
traffic to the lysosome for degradation; in MDA-MB-468 cells, the activated EGFR
internalizes to the early endosome and can be retained there for 24 hours [168].
This increases the duration of total receptor activity, as well as any
receptor:effector interactions in the early endosome. Finally, the kinetics of
EGFR-mediated apoptosis provide a large window (0-16 hours) to monitor the
many effectors activated by the receptor.
Despite these limitations to studying apoptosis, we were able to identify a
role for STAT3. There are multiple lines of evidence that support this role. First,
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the concentrations of EGF needed to activate STAT3 in MDA-MB-468 and A431
cells (Fig. 4.3) are consistent with the concentrations of EGF required to induce
apoptosis. Second, the kinetics of EGFR-mediated apoptosis (over the course of
16-48 hours [44, 165]) are consistent with a transcriptionally regulated event.
Third, STAT3 is a well-documented regulator of cell growth, albeit more
frequently having a positive effect. STAT3 has been associated with proliferative
activity in numerous malignancies, including glioblastoma [169], non-small cell
lung [170], and colorectal cancer [171]. In addition, STAT3-induced
tumorigenesis is linked to its constitutive activity in certain cancer cells [172-174].
Constitutive STAT3 activity was not observed in our MDA-MB-468 or A431 cells
(Figs. 4.2 and 4.3). In addition, there are data, consistent with ours, which
contradict these findings and implicate STAT3 as a mediator of cell death [175177].
The contradiction between our experimental results regarding STAT3
activity under pro-apoptotic conditions and the published data regarding the progrowth events of STAT3 led us to propose two opposing hypothesis. The first
hypothesis was that STAT3 is a mediator of apoptosis and that inhibition of the
protein would enhance cell viability. The second hypothesis was that the
induction of STAT3 activity was a compensatory reaction to the induction of
apoptosis promoted by another pathway (Fig. 4.6). Our subsequent experiments
indicate that STAT3 mediates apoptosis and is not a compensatory mechanism.
Previous reports have shown that the EGFR kinase directly activates
STAT3 [90], and that is likely the case in the MDA-MB-468 and A431 cells,
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particularly based on the kinetics of STAT3 phosphorylation. Given these
interactions require high doses of EGF and high receptor levels, this is likely a
pathological event rather than a physiological.
How STAT3 progresses to apoptosis is more ambiguous. It has been
previously reported that STAT3 activity directly promotes apoptosis in some
cancers [95, 146, 178, 179], and suppresses cancer cell colony formation and
invasion [180]. One possibility is that in MDA-MB-468 cells, like LNCaP cells,
STAT3 transcription is causing growth arrest and a block in cell cycle progression
[146]. This, coupled with strong proliferative EGFR signals, may result in a
signaling conflict for the cell that results in an apoptotic response. A second
option is that the high levels of STAT3 phosphorylation may increase the
magnitude and/or duration gene transcription that disrupts cell homeostasis and
causes cell death. Alternatively, high levels of activated STAT3 may lead to
aberrant STAT heterodimer formation. Previous studies have reported a role for
STAT1 in the induction of apoptosis [148, 164, 181]. More specifically, STAT1
has been implicated in EGFR-mediated apoptosis in A431 cells [138, 164] and
MDA-MB-468 cells [163]. Increased STAT3 activity may drive STAT1:STAT3
heterodimer formation which in turn allows STAT1 to drive apoptosis.
These changes in signaling may reflect mis-regulation of a normal
physiological process. STAT3-mediated apoptosis occurs during mammary gland
involution [96, 97], a complex process that returns mammary tissue to its prelactation, morphological state [182]. The initiation of this process is dependent on
the presence of milk in the alveoli after weaning, which elicits the synthesis of
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cytokines and growth factors that activate the STAT3 pathway to then
subsequently induce apoptosis [183-185]. The high concentrations of EGF ligand
in milk [186] are indirect evidence that point to the EGFR’s role within this
process. EGF-induced STAT3 activity and the subsequent induction of apoptosis
in MDA-MB-468 cells may therefore employ the same molecular mechanisms
required for mammary gland involution. Kreuzaler et al. have reported that
STAT3-mediated apoptosis in mammary gland involution entails enhancing
cathepsin B and L activity, while also downregulating their endogenous inhibitor,
serine protease inhibitor 2A (spi2A), in a process that occurs independently of
caspase 3, 6 and 7 activity [187]. Similarly, our data indicate that caspase 3 is
not a major factor in EGF-induced, STAT3-mediated apoptosis in MDA-MB-468
cells. Together, the cathepsin proteases, spi2A, and other effectors implicated in
mammary gland involution may be worth assessing in the context of EGFinduced, STAT3-mediated apoptosis (Depicted in Fig. 4.6A).
Another plausible explanation for this phenomenon is the pathway in
which cell death is induced. Caspase-1 activation promotes a particular form of
cell death that results from inflammatory responses, in a process known as
pyroptosis [188]. Pyroptosis has been documented to induce DNA fragmentation
[189] and has also been shown to cleave and activate PARP [68]. Given that
Caspase-1 inhibition is capable of blocking EGFR-mediated cell death in MDAMB-468 cells [48], pyroptosis may be an additional mode of cell death employed
by the EGFR. In addition to eliciting STAT3 activity, the Interleukin family of
cytokines has been well documented to promote inflammation and further
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progress inflammatory diseases [190-192]. Interferon-beta, a member of the
interferon family of cytokines, promotes apoptosis in pro-B cells in a STAT3dependent manner [145]. Thus, EGF-induced STAT3 activation and the
subsequent induction of pyroptosis would not be an unexpected finding.
These signaling differences must also be considered in the context of the
subcellular location in which they occur. There has been a well-established role
for spatial regulation of EGFR signaling by the endocytic pathway [193]. In MDAMB-468 cells, retention of the activated EGFR on the plasma membrane
promotes cell proliferation whereas when the EGF:EGFR complex internalizes
the cell undergoes apoptosis [44]. Further, the induction of apoptotic pathways is
linked to the endosomal accumulation of the EGF:EGFR complex [168]. Since
high concentrations of ligand are required for apoptosis, one must consider the
contribution of different routes of EGFR internalization. Sigismund et al. have
shown that low EGF ligand stimulation (1.5 ng/mL) primarily results in a clathrinmediated manner of EGFR internalization, whereas high ligand stimulation (20
ng/mL) promotes a clathrin-independent, lipid raft-mediated mode of endocytosis
[22]. These differing routes may also impact the composition of EGFR-containing
endosomes and which down stream signaling molecules are present.
Although all models are possible, in summarizing the literature, we favor
the notion that apoptosis results from the convergence of multiple signaling
events. Hyper-activated signaling, due to an increased number of active
receptors coupled with slowed down regulation, results in increased metabolic
and proliferative cell biology. The cell cannot accommodate these demands,
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resulting in a disrupted cellular homeostasis that cannot be restored. Ultimately,
the cell succumbs due to the stress of the saturated endocytic pathway. While
this does not identify a specific, pharmacological target, it suggests the potential
benefit of a multi-faceted approach that employs several low level, non-toxic
insults.
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CHAPTER V
SUMMARY AND FUTURE DIRECTIONS

A.

Restatement of Research Goals

The goal of the work described throughout this dissertation was to
elucidate the underlying mechanisms required for EGFR-mediated apoptosis to
occur. The paradox of EGFR-mediated cell growth versus EGFR-mediated
apoptosis is uncertain, and has remained so for decades. Identifying the
signaling effectors with direct implications in receptor-mediated apoptosis not
only contributes to the discipline of cellular biology, but also establishes a new
mode of therapeutically targeting cancers that are characterized by receptor
hyperexpression.

B.

Summary of Findings

We have identified two signaling molecules, which both have shown to
promote EGF-induced apoptosis. In Chapter III, we assessed and defined PKG
in this cellular process. Previous reports have implicated PKG activation as a
mediator of cell death in MDA-MB-468 cells, generally [86, 99]. Given this
information, we hypothesized that PKG might be mediating
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EGF-induced apoptosis, downstream, or possibly upstream of EGFR activation.
To differentiate between these two possibilities, we stimulated MDA-MB-468 cells
with agonists of PKG (8-Br-cGMP and 8-pCPT-cGMP-AM), and assessed for
phosphorylated EGFR. We also stimulated cells with EGF and assessed for a
substrate of PKG, phosphorylated VASP(Ser239). We found that the PKG
agonists did not elicit EGFR phosphorylation, where on the contrary, EGF ligand
induced PKG activity in a dose dependent manner. EGF-induced PKG
stimulation was confirmed in multiple cell lines (A431 and HeLa), further
supporting the notion that EGFR did in fact activate PKG, and PKG activity
selectively occurred downstream of receptor activation.
RNAi targeting PKG, and subsequent stimulation of EGFR resulted in a
significant attenuation of cell death, accompanied with a non-significant
attenuation of apoptosis, as measured by PARP and Caspase-3 cleavage. The
modesty in these findings may be attributed to the transfection efficiency of the
PKG siRNA (55%), which is consistent with previous reports [130], but
nonetheless marginal. From these data, we concluded that PKG is a mediator of
EGF-induce apoptosis in MDA-MB-468 cells, but not a very critical one.
To identify effectors with more pertinent roles in EGFR-mediated
apoptosis, we began in Chapter IV by subjecting MDA-MB-468 cells to a
thorough effector screen, assessing the phosphorylation pattern of effectors that
are well-established substrates of the EGFR (MAPK, Src, AKT, BAD, and
STAT3). We subjected MDA-MB-468 cells to conditions in which the cells
undergo EGFR-mediated cell growth, and conversely EGFR-mediated apoptosis,
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and assessed the phosphorylation patterns of these five effectors for their
potential association with one of these two conditions, preferentially. STAT3
activity was the only effector with a preferentially robust increase in
phosphorylation at conditions that coincidently induce apoptosis.
Our findings helped develop the hypothesis that STAT3 was a mediator of
EGF-induced apoptosis. Given the many reports depicting STAT3 portraying a
pro-proliferative role in cancer [169-171], we developed the alternative
hypothesis that STAT3 upregulation was the result of a compensatory
mechanism, in an attempt to rescue the cell from EGFR-mediated apoptosis.
Logically, in order to assess both of these hypotheses, we needed to abrogate
STAT3 activity and or gene expression, activate the EGFR, and subsequently
assess the outcome of this on receptor-mediated apoptosis. A rise in viability and
an ultimate attenuation of apoptosis would favor the notion of STAT3 as a
mediator of EGF-induce apoptosis; similar to our findings with PKG. On the
contrary, observing an increase in apoptosis, and a further reduction in viability
would define the role of STAT3 in pro-proliferative, compensatory signaling
cascade.
We began our investigation by employing commercially available
antagonists of STAT3, Stattic and S3I-201. Inhibitor treatments in the presence
of EGF resulted in a dose dependent decrease in MDA-MB-468 and A431 cell
viability. Biochemical analyses of the inhibitor treatments in the presence of EGF
resulted in a dose dependent increase in apoptosis, which appeared to be
substantially greater than in cells treated with EGF alone. Together, these
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findings favored our “pro-proliferative, compensatory” STAT3 hypothesis.
However, further assessment of the inhibitor biochemistry revealed that with a
dose dependent decrease in STAT3 activity, EGFR phosphorylation was
coincidently decreased as well. We concluded that this was due to one of two
possibilities. Either the STAT3: EGFR complex entailed a tightly coupled
relationship between the two proteins, resulting in a dual-inhibitory effect, or
these STAT3 antagonists were exhibiting off-target, non-specific cytotoxicity. The
first possibility was not favored, considering previous reports that have indicated
a low affinity of STAT3 for EGFR in both A431 and MDA-MB-468 cells [194]. The
second possibility seemed more likely, given that our viability data showed no
attenuation of inhibitor with EGF treatment in comparison to EGF treatment
alone. Therefore, we hypothesized that Stattic and S3I-201 were exhibiting offtarget effects, in vitro.
To determine if the STAT3 inhibitors were in fact non-specifically cytotoxic,
we employed the PC3 cell line, which contains very low EGFR expression, and is
completely void of STAT3. A cell line without STAT3 expression biochemically
functions and maintains cellular homeostasis independent of STAT3 activity.
Therefore, the addition of these STAT3 antagonists to the PC3 cells should result
in no deleterious effects on cell viability. The PC3 cell line however did exhibit a
dose dependent decrease in cell viability as a result of the STAT3 inhibitors. The
Stattic inhibitor was shown to be very cytotoxic (consistent within the MDA-MB468 and A431 cell lines), more than our positive control for cell death, STS.
Additionally, the lack of STAT3 expression and low level EGFR expression in

98

PC3 cells further suggests that these inhibitors promote their cytotoxic effects
through multiple, unknown pleiotropic mechanisms. Although these studies did
not contribute any further insight to the cellular mechanism of STAT3 activity in
EGFR-mediated apoptosis, they are a paramount contribution in terms of the use
of the clinical use of STAT3 antagonists. STAT3 inhibitors have been well
documented to be clinically beneficial in the treatment of cancer [195-197] and
muscle degeneration [198, 199]. In addition to proving their limitations, our
reports of STAT3 antagonist-induced, off-target interactions suggest the use of
caution in regard to their therapeutic administration.
Continuing on within our research, we elected to employ STAT3 siRNA as
a more selective mode of abrogating STAT3 activity in the MDA-MB-468 cell line.
STAT3 knock down cells displayed a significant reduction in EGFR-mediated
apoptosis, as measured by PARP cleavage. Although Caspase-3 cleavage was
also attenuated, the results were however statistically insignificant. Nonetheless,
these data strongly depicted STAT3 as a critical mediator of EGF-induced
apoptosis, via PARP activation.
To further strengthen our findings, we decided to assess STAT3 activity
independent of EGFR-activation. First, we subjected MDA-MB-468 cells to a
cytokine (OSM) that has been documented to induce STAT3 activation. The
results of these studies indicate that with a simultaneous activation of STAT3, a
sustained increase in PARP and Caspase-3 cleavage was also observed over
time. In addition to STAT3 activation, OSM induced a time-dependent increase
pVASP stimulation. This further supported STAT3 as a mediator of apoptosis,
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while also suggesting it does so through activation of our initial effector
candidate, PKG. In our final assessment if STAT3, we stimulated MDA-MB-468
cells with concentrations of STS capable of inducing cell stress without causing
catastrophic cellular damage. Our goal was to establish whether or not STAT3
activity was induced in response to cell stress generally, and also to determine if
STAT3 activation could be achieved independently of cytokine or growth factor
mediation. The results displayed no induction of STAT3 activity with STS
activation, suggesting that cytokine or growth factor activation is required to
simulate STAT3 and promote its apoptotic effects. In summary of Chapter IV, our
data provide evidence of a novel, molecular interaction between EGFR and
STAT3, with EGFR requiring STAT3 to exert its apoptotic effects in MDA-MB-468
cells.

C. Significance of Findings

The significance among this research lies within the identification of key,
molecular links in-between initial EGFR activation and the ultimate induction of
apoptosis. PKG and STAT3 differ both structurally, and in terms of their
physiological implications. However, both of these effectors contribute to an
EGF-induced apoptotic fate in MDA-MB-468 cells. Although PKG has shown to
play a more minor role in receptor-mediated cell death, preliminary data suggests
that STAT3 may signal to and stimulates PKG and subsequent pVASP activity
(Figure 4.4) Not only does this support the roles of PKG and STAT3 in promoting
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receptor-mediated apoptosis, but it also provides some insight in terms of their
correlation, and the sequence of their signaling within this subcellular
mechanism.
The role of STAT3 in tumor cell formation has been well established both
within the literature and this dissertation. This has been shown to be due to
constitutive activation of STAT3 in certain cancer cell lines [172-174]. The MDAMB-468 cell line is among those documented to exhibit constitutive STAT3
activity [88, 200]; however, consistent with our findings, some studies have
shown that STAT3 is not constitutively active in MDA-MB-468 cells [175-177].
The discrepancy among these results remains inexplicit. In regard to our
research, we employed low-passage MDA-MB-468 cells, which were stringently
restricted from long-term propagation. In addition, we thoroughly optimized and
executed proper conditions for serum starvation for each of the cell lines of use.
Although these practices are quite simple by nature, they are pivotal in the proper
maintenance of a tissue culture cell line in order to avoid cellular transformation.
Each of these components may be a plausible explanation for the contradictory
reports of STAT3 constitutive activity in MDA-MB-468 cells.
Our findings identify a minor mediator (PKG) and a more prominent
mediator (STAT3) of EGF-induced cell death and apoptosis. In addition to
expanding the knowledge to the mechanisms of EGFR-mediated apoptosis, this
research suggests that the addition of PKG and or STAT3 agonists might
increase the efficacy of current cancer therapeutics that target EGFRoverexpressed cancers.
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D.

Strengths and Weaknesses

1. Strengths
There are several strengths of the research described in this dissertation.
The first being the sensitivity and specificity of western blotting. As low as 20 ng
of protein can be resolved on an SDS PAGE and still detected upon immunoblot
analyses [201]. Additionally, the antibody-antigen interaction provides a very
specific mode of protein identification, which when properly optimized, provides
results with very minimal cross-reactivity upon assessing proteins of similar sizes
[202].
The unambiguous readout of studies that assess subcellular signaling
mechanisms is another advantage of this project. Thorough identification of
proteins and their roles in signaling cascades does not elicit much doubt or
possibility of multiple interpretations. It is possible that a particular protein may be
employed in multiple, non-correlated signaling cascades; however, through the
use of pharmacological inhibitors and or RNAi, it is feasible to distinguish
whether or not that particular protein is a critical mediator in a pathway of
interest. Within this project specifically, this was advantageous in regard to our
experimental hypotheses. Had our initial hypothesis (in our assessments of both
PKG and STAT3) proven to be incorrect, our hypotheses were excellently
designed in such a manner that the alternative outcome would have still provided
novel contributions to the discipline of receptor biology.
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2. Weaknesses
The use of a tissue culture model system does have some limitations. It is
useful in terms of conducting preliminary work; however, this model does not
take into account the complexity of an entire living organism. Although our
findings that PKG and STAT3 attenuate human breast cancer cell growth, they
both may possibly exhibit unintended, deleterious affects in other tissue. A major
progression within this study and project would be to assess our findings in a
more molecularly complex organism.
Another weakness of this work lies in the lack of variation among the
assays employed, more specifically in terms our analyses of apoptosis. The use
of more diverse and quantitative assays to assess apoptosis would have
definitely strengthened our data and overall conclusions. We did attempt to
employ more quantitative apoptotic assays, including: Annexin V (BD
Pharmingen, Franklin Lakes, NJ), which asseses for Phosphatidylserine
translocation; ApoStrand ELISA (Enzo, Farmingdal, NY), which assess single
strand DNA in apoptotic cells; and a Caspase- 3/7 Assay kit (Anaspec, Fremont,
CA), which assesses the kinetics of Caspase-3 and Caspase-7 activity. Upon
employing all of these assays, we observed no significant induction of apoptosis
in our EGF treated MDA-MB-468 cells, coincident with a substantially high
induction of apoptosis in our serum free, viable cells. This may be attributed to
employing a sample size below the limit of detection or the need for further assay
optimization. Reports have shown that in cell lines with high EGFR and Erb-B2
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expression, EGFR-mediated apoptosis induced marginal Caspase-3 activation
[132]. Our Caspase-3 cleavage data are consistent with this report, which
suggests that Caspase-3 may not be critical mediator in EGF-induced apoptosis.
Therefore, there may be other modes of cell death employed to achieve an
EGFR-mediated apoptotic fate. These modes and the respective assays to
assess them are components that will need to be considered in order to further
progress this project.
Although the defect in EGFR trafficking provides an excellent model to
study receptor signaling from the endosomes, this does however present some
limitations. In MDA-MB-468 cells, the activated EGFR accumulates on the
limiting membrane of the early endosome, and can be retained there for up to 24
hours [45]. This increases the duration of receptor activity while also providing a
relatively large window for receptor-mediated apoptosis to occur. Due to this, it
was challenging to determine the most optimal time points to assess EGFRmediated apoptosis and the effectors that were implicated with it.

E.

Future Directions

This work has elucidated some of the signaling mechanisms that are
implicated in EGF-induced apoptosis. However, this has inevitably raised more
questions, requiring additional assessments to progress this project and to
further expand upon the molecular mechanisms of receptor-mediated apoptosis.
The first approach in progressing this project entails assessing PKG and STAT3
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activity relative to one another in MDA-MB-468 cells. Data from chapter IV
suggest that EGFR-independent STAT3 activity elicits downstream activation of
PKG prior to the ultimate induction of apoptosis. It would be interesting to confirm
if STAT3 is in fact upstream and necessary for PKG activation to occur. Doing so
would require PKG inhibition, and subsequent stimulation of STAT3 activity (with
OSM), prior to ultimately assessing VASP phosphorylation. Following this, it
would be interesting to assess PKG and STAT3 dual-knock down, and the
ultimate outcome of this on EGFR-mediated apoptosis in MDA-MB-568 cells.
Observing an even greater attenuation of apoptosis in cells with impaired PKG
and STAT3 activity would further confirm their roles in receptor-mediated
apoptosis, and would also define the correlation between PKG-induced and
STAT3- induced cell death signaling pathways.
The next approach involves assessing the defect in EGFR trafficking
observed in the MDA-MB-468 cells. It is our belief that the slowed kinetics of
receptor degradation within this cell line is the more critical underlying culprit
behind EGFR-mediated apoptosis. The EGFR has been shown to accumulate on
the limiting membrane of the early endosome in these cells [45]. In addition to
increasing the duration of total receptor activity, this defect also initiates the
induction of apoptosis at the early endosome. This is suspected to be due to the
saturation of the endocytic pathway, which subsequently induces cell stress.
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a
phosphatase that belongs to the subclass of dual-specificity enzymes. It is
capable of dephosphorylating serine, threonine or tyrosine residues on protein
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targets [203]. In addition, PTEN has been shown to be necessary to promote
EGFR trafficking from early to late endosomes [204], and has been shown to be
void in MDA-MB-468 cells [205]. Expression of PTEN into MDA-MB-468 cells
resulted in ligand-induced degradation of EGFR [204]. Additionally, genetic
deletion of STAT3 and PTEN has been shown to trigger tumor progression in a
mouse model for prostate cancer [180], suggesting a co-dependency among
these proteins in terms of their role in cancer progression. If we were to transfect
PTEN into MDA-MB-468 cells, while simultaneously knocking down STAT3 (and
PKG), it would be interesting if we could enhance the kinetics of EGFR trafficking
and simultaneously reduce the rate of receptor-mediated apoptosis. This would
not provide a major contribution in terms of the cancer biology aspect of this
project, but it would however further reveal additional components that contribute
to the underlying mechanisms of EGF-induced apoptosis.
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